 
   
TPL-000052_v11 Macitentan / ACT -[ADDRESS_327752] device 
implantation 
Protocol AC -055-205 
SOPRANO: Macitentan in pulmonary hypertenS iOn Post-left ventRiculAr assist device 
implaNtatiOn 
A prospective, multicenter, double- blind, randomized, placebo -controlled, 
parallel-group study to assess the efficacy and safety of macitentan in patients  
with pulmonary hypertension after left ventricular assist device implantation  
 Study Phase: 2 
Status and version:  Version 3  
Date: 10 March  2017 
Document type  Amended global protocol  
Actelion document number 
(Doc No.):  D-17.[ADDRESS_327753]. It is understood that this information will not be disclo sed to others without written 
authorization from Actelion Pharmaceuticals Ltd, except to the extent necessary to obtain informed consent from those persons to whom the study treatment may be administered.  
   
[STUDY_ID_REMOVED]
Macitentan / ACT-[ADDRESS_327754]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 2/[ADDRESS_327755] South San Francisco, CA [ZIP_CODE] [LOCATION_003] 
Clinical Trial Physician  Mona Selej , M.D., M.S.  / Associate Director, Medical 
Affairs 
   
Fax   
e-mail   
MEDICAL HOTLINE  
 Site-specific toll telephone numbers and toll -free 
numbers for the Medical Hotline can be found in the 
Investigator Site File  
 
ACTELION CONTRIBUTORS TO THE PROTOCOL  
Clinical Trial Scientist  Mona Selej , M.D., M.S. / Associate Director, Medical 
Affairs  
  
Fax 
  
Clinical Trial Statistician  Carol Zhao , M.S. / Associate Director, Biostatistics  
   
Fax  
e-mail .  
Clinical Project Manager  , B.S.N, R.N. / Associate Director, 
Clinical Operations  
   
Fax +  
e-mail   
Lead Medical Science 
Liaison , Ph.D. / Senior MSL  
   
Fax   
e-mail   
Drug Safety Physician  / Senior Drug Safety Physician  
   
Fax   
e-mail   
[COMPANY_003]
P
P
D
P
P
D
P
P
D
P
P
D
[COMPANY_003]
P
P
D
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
P
P
D
[COMPANY_003]
[COMPANY_003]
P
P
D
P
P
D
[COMPANY_003]
P
P
D
P
P
D
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
P
P
D
[COMPANY_003]
Macitentan / ACT-[ADDRESS_327756]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 3/[ADDRESS_327757] VENDOR INFO RMATION 
 
CENTRAL ECHO 
LABORATORY  Cardiocore Lab, LLC d/b/a BioTelemetry 
Research 
One Preserve Parkw ay, Suite [ADDRESS_327758] 
Raleigh, NC [ZIP_CODE], U.S.A  
 
DRUG DEPOT  Almac Group Ltd.  
Almac House, 20 Seagoe Industrial Estate 
Craigavon, BT63 5QD, U.K.  
 
ELECTRONIC DATA CAPTURE/ 
DATA MANAGEMENT  Pharmaceutical Research Associates, Inc.  
[ADDRESS_327759] 
Raleigh, NC [ZIP_CODE], U.S.A  
 
RANDOMIZATION  PAREXEL International. PAREXEL 
Informatics, 4 Canal Stree t, Castle Wharf, 
Nottingham. NG1 7EH. [LOCATION_006].  
 
 
Macitentan / ACT-[ADDRESS_327760]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 4/103 Confidential  Doc No D-17.154 
 
SIGNATURE [CONTACT_42954] A CTELION PHARMACEUTICALS LTD 
Hereinafter called Actelion  
 Treatment name / number  
Macitentan / ACT -[ADDRESS_327761] device implantation  
Protocol number, study acronym, study title 
AC-055-205, SOPRANO: A prospective, multicenter, double -blind, randomized, 
placebo-controlled, parallel -group study to assess the efficacy and safety of macitentan in 
patients with pulmonary hypertension after lef t ventricular assist device implantation  
 I approve the design of this study.    
 
[COMPANY_003]
Macitentan / ACT-[ADDRESS_327762]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 5/103 Confidential  Doc No D-17.154 
 
INVESTIGATOR SIGNATURE [CONTACT_208317] / number  
Macitentan / ACT -[ADDRESS_327763] device implantation  
Protocol number, study acronym, study title 
AC-055-205, SOPRANO: A prospective, multicenter, double -blind, randomized, 
placebo-controlled, parallel -group study to assess the efficacy and safety of macitentan in 
patients with pulmonary hypertension after left ventricula r assist device implantation . 
I agree to the terms and conditions relating to this study as defined in this protocol, the electronic Case Report Form (eCRF), and any other protocol -related documents. I fully 
understand that any changes instituted by [CONTACT_093](s) without previous agreement with the sponsor would constitute a protocol deviation, including any ancillary studies or procedures performed on study subjects (other than those procedures necessary for the wellbeing of the subjects). I agree to  conduct this study in accordance with the Declaration of Helsinki principles, 
International Council for  Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, 
and applicable regulations and laws. I will obtain approval by [CONTACT_180473] (IRB/IEC) prior to study start and signed 
informed consent from all subjects included in this study. If an amendment to the protocol is necessary, I will obtain approval by [CONTACT_2717]/IEC and ensure approval by [CONTACT_12721] (if applicable) have been obtained before the implementation of changes described in the amendment. I will allow direct access to source documents and study facilities to sponsor representative(s), particularly monitor(s) and auditor(s), and agree to inspection by [CONTACT_118247]/IEC representative. I will ensure that 
the study treatment(s) supplied by [CONTACT_180474]. I confirm herewith that the sponsor is allowed to enter and utilize my professional contact [CONTACT_180475]. 
 Country Site 
number Town Date  Signature  
[INVESTIGATOR_678]        
[CONTACT_180555] / ACT-[ADDRESS_327764]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 6/[ADDRESS_327765] VENDOR INFORMATION  .........................................................................3  
SUBSTANTIAL GLOBAL AMENDMENT 2  .................................................................16  
PROTOCOL SYNOPSIS AC-055-205 .............................................................................19  
PROTOCOL  ......................................................................................................................30  
1 BACKGROUND  .........................................................................................................30  
1.1 Indication  ......................................................................................................30  
1.2 Epi[INVESTIGATOR_623] ................................................................................................30  
1.3 Current management .....................................................................................31  
1.4 Endothelin-1 and pulmonary hypertension ...................................................32  
1.5 Macitentan  ....................................................................................................33  
1.5.1 Nonclinical results  ............................................................................33  
1.5.2 Phase 1 results  ...................................................................................33  
1.5.3 Phase 2 results  ...................................................................................33  
1.5.4 Phase 3 efficacy results in PAH  ........................................................34  
1.5.5 Summary of potential risks and risk management ............................34  
1.6 Purpose and rationale of the study ................................................................37  
2 STUDY OBJECTIVES  ...............................................................................................37  
2.1 Primary objective(s)  .....................................................................................[ADDRESS_327766] POPULATION ..........................................................................................42  
Macitentan / ACT-[ADDRESS_327767]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 7/[ADDRESS_327768] population description .....................................................................42  
4.2 Rationale for the selection of the study population ......................................42  
4.3 Inclusion criteria  ...........................................................................................42  
4.4 Exclusion criteria  ..........................................................................................43  
4.5 Criteria for women of childbearing potential  ...............................................44  
4.5.1 Definition of childbearing potential ..................................................44  
4.5.2 Acceptable methods of contraception  ...............................................45  
4.6 Medical history  .............................................................................................46  
5 TREATMENTS  ..........................................................................................................46  
5.1 Study treatment .............................................................................................46  
5.1.1 Investigational treatment: description and rationale  .........................46  
5.1.2 Comparator(s) and/or matching placebo: description and rationale ............................................................................................46
 
5.1.3 Study treatment administration  .........................................................46  
5.1.4 Treatment assignment  .......................................................................47  
5.1.5 Blinding ............................................................................................47  
5.1.6 Unblinding ........................................................................................47  
[IP_ADDRESS] Unblinding for final analyses .................................................. 47 
[IP_ADDRESS] Unblinding ............................................................................... 47 
[IP_ADDRESS] Unblinding for S[LOCATION_003]Rs  .......................................................... 48 
[IP_ADDRESS] Emergency procedure for unblinding ...................................... 48 
5.1.7 Study treatment supply .....................................................................48  
[IP_ADDRESS] Study treatment packaging and labeling  ................................. 48 
[IP_ADDRESS] Study treatment distribution and storage ................................. 49 
[IP_ADDRESS] Study treatment dispensing ..................................................... 50 
[IP_ADDRESS] Study treatment return and destruction ................................... 50 
5.1.8 Study treatment accountability and compliance with study treatment ...........................................................................................51
 
[IP_ADDRESS] Study treatment accountability ................................................ 51 
[IP_ADDRESS] Study treatment compliance .................................................... 51 
5.1.9 Study treatment dose adjustments and interruptions ........................51  
5.1.10 Premature discontinuation of study treatment ..................................52  
5.1.11 Study-specific criteria for interruption / premature 
discontinuation of study treatment ....................................................53  
5.2 Previous and concomitant therapy ................................................................56  
5.2.1 Definitions  ........................................................................................56  
5.2.2 Reporting of previous/concomitant therapy in the eCRF .................56  
5.2.3 Allowed concomitant therapy ...........................................................56  
5.2.4 Prohibited concomitant therapy ........................................................56  
Macitentan / ACT-[ADDRESS_327769]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 8/103 Confidential  Doc No D-17.154 
 
5.3 Allowed LVAD flow rate  .............................................................................57  
6 STUDY ENDPOINTS  ................................................................................................57  
6.1 Efficacy endpoints ........................................................................................57  
6.1.1 Primary efficacy endpoint(s) ............................................................57  
6.1.2 Secondary efficacy endpoints ...........................................................57  
6.1.3 Exploratory efficacy endpoints  .........................................................57  
6.2 Safety endpoints ...........................................................................................58  
6.3 Biomarker  endpoints .....................................................................................58  
7 STUDY ASSESSMENTS ...........................................................................................58  
7.1 Screening/Baseline assessments  ...................................................................59  
7.2 Efficacy assessments ....................................................................................60  
7.2.1 Hemodynamic measurements - right heart catheterization  ...............60  
7.2.2 WHO functional class  .......................................................................61  
7.2.3 Serum NT -proBNP ...........................................................................61  
7.2.4 Echocardiography .............................................................................61  
7.2.5 Clinical events  ...................................................................................62  
7.2.6 Duration of heart failure hospi[INVESTIGATOR_059]  ...........................................62  
7.2.7 Glomerular filtration rate  ..................................................................62  
7.3 Safety assessments  ........................................................................................62  
7.3.1 Vital signs  .........................................................................................62  
7.3.2 Weight and height  .............................................................................63  
7.3.3 Physical examination ........................................................................63  
7.3.4 Laboratory assessments ....................................................................63  
[IP_ADDRESS] Type of laboratory ................................................................... 63 
[IP_ADDRESS] Laboratory tests  ....................................................................... 65 
7.4 Biomarker and genetic assessments .............................................................66  
8 SCHEDULE OF VISITS  ............................................................................................66  
8.1 Screening period ...........................................................................................66  
8.1.1 Screening (Visit 1)  ............................................................................66  
8.2 Double-blind study tr eatment period  ............................................................67  
8.2.1 Randomization (Visit 2)  ....................................................................67  
8.2.2 Week 4 (Visit 3)  ................................................................................68  
8.2.3 Week 8 (Visit 4)  ................................................................................69  
8.2.4 End-of-Treatment (Visit 5) ...............................................................69  
8.2.5 End-of-Study (Visit 6)  ......................................................................70  
8.2.6 Unscheduled Visits (U1, U2, etc) .....................................................70  
Macitentan / ACT-[ADDRESS_327770]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 9/[ADDRESS_327771]-STUDY TREATMENT/MEDICAL 
CARE ..........................................................................................................................70  
9.1 Study completion ..........................................................................................70  
9.2 Premature withdrawal from study  ................................................................71  
9.3 Premature termination or suspension of the study ........................................71  
9.4 Medical care of subjects after study completion/withdrawal from study ..............................................................................................................72
 
10 SAFETY DEFINITIONS A ND REPORTING REQUIRE MENTS ...........................72  
10.1 Adverse events ..............................................................................................72  
10.1.1 Definitions of adverse events ............................................................72  
10.1.2 Intensity of adverse events  ................................................................73  
10.1.3 Relationship to study treatment ........................................................74  
10.1.4 Adverse events associated to study design or protocol-mandated procedures ..........................................................74
 
10.1.5 Reporting of adverse events ..............................................................74  
10.1.6 Follow-up of adverse events  .............................................................74  
10.2 Serious adverse events  ..................................................................................75  
10.2.1 Definitions of serious adverse events  ...............................................75  
[IP_ADDRESS] Serious adverse events  ............................................................. 75 
10.2.2 Reporting of serious adverse events  .................................................75  
10.2.3 Follow-up of serious adverse events  .................................................76  
10.2.4 After the 30 -day follow-up period ....................................................76  
10.2.5 Reporting procedures ........................................................................76  
10.3 Pregnancy .....................................................................................................77  
10.3.1 Reporting of pregnancy ....................................................................77  
10.3.2 Follow-up of pregnancy ....................................................................77  
10.4 Study safety monitoring ................................................................................77  
11 STATISTIC AL METHODS  .......................................................................................77  
11.1 Analysis sets .................................................................................................78  
11.1.1 Screened Analysis Set  .......................................................................78  
11.1.2 Safety Set  ..........................................................................................78  
11.1.3 Full Analysis Set ...............................................................................78  
11.1.4 Modified Full Analysis Set ...............................................................78  
11.1.5 Per-Protocol Set  ................................................................................78  
11.1.6 Usage of the analysis sets .................................................................78  
11.2 Variables  .......................................................................................................79  
11.2.1 Primary efficacy variable(s)  ..............................................................79  
Macitentan / ACT-[ADDRESS_327772]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 10/103 Confidential  Doc No D-17.154 
 
11.2.2 Secondary efficacy variables  ............................................................79  
11.2.3 Exploratory efficacy variables  ..........................................................79  
11.2.4 Safety variables  .................................................................................80  
11.3 Description of statistical analyses  .................................................................80  
11.3.1 Overall testing strategy  .....................................................................80  
11.3.2 Analysis of the primary efficacy variable(s)  .....................................80  
[IP_ADDRESS] Hypotheses and statistical model ............................................ 80 
[IP_ADDRESS] Handling of missing data ......................................................... 81 
[IP_ADDRESS] Main analysis ........................................................................... 81 
[IP_ADDRESS] Supportive/sensitivity analyses ............................................... 82 
[IP_ADDRESS] Subgroup analyses ................................................................... 82 
11.3.3 Analysis of the s econdary efficacy variable(s)  .................................82  
11.3.4 Analysis of the exploratory efficacy variable(s)  ...............................82  
11.3.5 Analysis of the safety variable(s)  ......................................................83  
[IP_ADDRESS] Adverse events ........................................................................ 83 
[IP_ADDRESS] Laboratory variables  ................................................................ 84 
[IP_ADDRESS] Vital signs and body weight .................................................... 84 
11.4 Interim analyses  ............................................................................................85  
11.5 Sample size  ...................................................................................................85  
11.5.1 Sample size justification  ...................................................................85  
11.5.2 Sample size sensitivity  ......................................................................85  
12 DATA HANDLING  ....................................................................................................86  
12.1 Data collection  ..............................................................................................86  
12.2 Maintenance of data confidentiality  .............................................................86  
12.3 Database management and quality control ...................................................87  
13 PROCEDURES AND GOOD CLINICAL PRACTICE  .............................................88  
13.1 Ethics and Good Clinical Practice  ................................................................88  
13.2 Independent Et hics Committee / Institutional Review Board  ......................88  
13.3 Informed Consent  .........................................................................................88  
13.4 Compensation to subjects and investigators .................................................89  
13.5 Protocol adherence/compliance  ....................................................................89  
13.6 Protocol amendments  ...................................................................................90  
13.7 Essential documents and retention of documents .........................................90  
13.8 Monitoring ....................................................................................................91  
13.9 Investigator site file  ......................................................................................92  
13.10 Audit .............................................................................................................92  
13.11 Inspections ....................................................................................................92  
13.12 Reporting of study results and publication ...................................................93  
Macitentan / ACT-[ADDRESS_327773]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 11/[ADDRESS_327774] OF TABLES  
 Table 1
 Visit and assessment schedule  ..................................................................... 28  
Table 2 Treatment effects (differences on log -scale as well as % reduction  
versus placebo), variability in integrated analysis of four studies (AC-052-366, AC-052-364, AC-055-302 and AC- 055E201), and 
associated sample size for 80% power.  ........................................................ [ADDRESS_327775] OF APPENDICES  
 Appendix 1
 WHO functional classification of pulmonary hypertension ......................... 99  
Appendix 2  Glossary ...................................................................................................... 100  
  
Macitentan / ACT-[ADDRESS_327776]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 12/[ADDRESS_327777] OF ABBREVIATIONS AND ACRONYMS 
2D  Two-dimensional  
3D  Three-dimensional  
6MWD  6-minute walk distance  
A’  Tricuspid peak diastolic annular velocity a ’ 
AE  Adverse event 
ALT  Alanine aminotransferase 
ANCOVA   Analysis of covariance  
AST  Aspartate aminotransferase  
BMI  Body mass index 
BP  Blood pressure 
BSA  Body surface area  
BUN  Blood urea nitrogen  
CI  Cardiac index  
CL  Confidence limit 
CO  Cardiac output  
CRA  Clinical research associate  
CRO  Contract Research Organization  
CV  Curriculum vitae  
CVs  Coefficients of variati on 
CYP3A4  Cytochrome P450 isozyme 3A4 
DBP  Diastolic blood pressure  
DoA  Delegation of Authority  
DT  Destination therapy  
E’  Tricuspid peak diastolic annular velocity e ’ 
ECG  Electrocardiogram  
eCRF  Electronic case report form  
EOS  End-of-Study  
EOT  End-of-Treatment  
ERA  Endothelin receptor antagonist  
ET-1  Endothelin-1 
Macitentan / ACT-[ADDRESS_327778]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 13/103 Confidential  Doc No D-17.154 
 
ETA  Endothelin receptor A  
ETB  Endothelin receptor B  
FAS  Full Analysis Set 
FC  Functional class  
FDA  Food and Drug Administration 
FEV1  Forced expi[INVESTIGATOR_3741] 1 second  
FVC  Forced vital capacity  
GCP  Good Clinical Practice  
GDF-15  Growth differentiation factor -15 
GFR  Glomerular filtration rate  
GMP  Good Manufacturing Practice 
GMR  Geometric mean ratio  
HF  Heart failure  
hsCRP  High sensitivity C- reactive protein  
hs-cTnT  High sensitivity cardiac troponin T 
i.v.  Intravenous 
IB  Investigator’s brochure 
ICF  Informed consent form 
ICH  International Conference On Harmonisation 
IDMC  Independent Data Monitoring Committee 
IEC  Independent Ethics Comm ittee 
IL-[ADDRESS_327779]  
ISF  Investigator site file  
IxRS  Interactive Voice/Web Response System  
LDH  Lactate dehydrogenase  
LFT  Liver function test  
Macitentan / ACT-[ADDRESS_327780]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 14/[ADDRESS_327781] device  
RVF  Right ventricular failure  
RVFAC  Right ventricular fractional area change  
RVLS  Global RV longitudinal strain  
RVSI  Right ventricular sphericity index  
s.c.  Subcutaneous 
S’  Tricuspid peak annular velocity s’ 
SAE  Serious adverse event  
SAP  Statistical analysis plan  
SBP  Systolic blood pressure  
SD  Standard deviation  
SIV  Site initiation visit  
SOC  System organ class  
SOP  Standard operating procedure 
Macitentan / ACT-[ADDRESS_327782]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 15/[ADDRESS_327783]  Upper limit of the normal range  
WHO  World Health Organization 
WU  Wood unit 
 
Macitentan / ACT-[ADDRESS_327784]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 16/[ADDRESS_327785] 
device Screening window to 90 days.  
Other changes include:  
• Addition of a Glossary to clarif y protocol terms.  
• Sample size re- estimation updates based on recently released study results 
(e.g., MERIT).  
• Re-definition of Baseline right heart catheterization (RHC) with emphasis on the 
required thermodilution method for Baseline and Week 12 ( End-of-Treatment) RHC.  
• Removal of any language pertaining to pulmonary artery catheter (PAC) assessments (as PAC serving as the source of Baseline RHC hemodynamics is expected to be 
rare). 
• Addition of the requirement that Randomization must take place within 14 days of Baseline RHC (new inclusion criterion).  
• General text edits for greater clarity in study execution and training.  
• Description of the core responsibilities of the Clinical Event Committee and Core Hemodynamics Laboratory. 
• Primary, secondary and explora tory efficacy analyses to be performed on the Full 
Analysis Set ( FAS), no longer the modified FAS. 
Changes to the protocol  
Two versions of the amended protocol will be prepared: 1) a clean version and 2) a Word comparison document, showing deletions and insertions in comparison to the previous 
protocol version. 
                                                 
1 This amendment is global amendment 2, applicable to all sites in the study. The previous amendment was local 
amendment 1 (US). However, as this study only has sites in the US, the amendment type has be en revised to 
‘global’ to clarify that it is applicable to all sites in the study.  
Macitentan / ACT-[ADDRESS_327786]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 17/[ADDRESS_327787] also been made to the corresponding sections of the protocol synopsis and to the Table of A ssessments:  
1.5.5  Summary of potential risks and risk management 3.1  Study design 3.3  Study committees  4.2  Rationale for the selection of the study population 4.3  Inclusion criteria  
4.4  Exclusion criteria  
5.1.3  Study treatment administration  
[IP_ADDRESS]  Unblinding [IP_ADDRESS].2 Study treatment storage  [IP_ADDRESS]  Study treatment dispensing  [IP_ADDRESS]  Study treatment compliance  5.1.11 Study- specific criteria for interruption / premature discontinuation of study 
treatment 
5.2.1  Definitions  
5.2.3  Allowed concomitant therapy 5.3  Allowed LVAD flow rate  
6.1.1  Primary efficacy endpoint(s) 6.3  Biomarker endpoints 7.2.1  Hemodynamic measurements – right heart catheterization  
7.2.4  Echocardiography [IP_ADDRESS]  Type of laboratory 7.4  Biomarker and genetic assessments 
8.1.1  Screening (Visit 1)  
8.2.1  Randomization (Visit 2)  
10.1.5  Reporting of adverse events 10.2.2  Reporting of serious adverse events  
10.3.1  Reporting of pregnancy 11.1.6  Usage of the analysis sets 
[IP_ADDRESS] Handling of missing data [IP_ADDRESS] Main analysis [IP_ADDRESS] Supportive/sensitivity analyses 11.3.3  Analysis of the secondary efficacy variable(s)  
11.3.4  Analysis of the exploratory efficacy variable(s)  
11.5.1  Sample size justification   
11.5.2  Sample size sensitivity  
13.8  Monitoring 
Macitentan / ACT-[ADDRESS_327788]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 18/103 Confidential  Doc No D-17.154 
 
Summary of previous amendments  
Amendment  Date Main reason(s)  
[ADDRESS_327789] consistency across the sections of 
the protocol.  
 
Macitentan / ACT-[ADDRESS_327790]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 19/[ADDRESS_327791] device implantation.  
ACRONYM  SOPRANO: Macitentan in pulmonary hyperten SiOn Post-left 
ventRiculAr assist device implaN tatiOn 
OBJECTIVES  Primary objective  
To evaluate the effect of macitentan 10 mg on pulmonary 
vascular resistance (PVR) as com pared to placebo in subjects 
with pulmonary hypertension (PH) after left ventricular assist 
device (LVAD) implantation.  
Secondary objectives  
• To evaluate the effect of macitentan 10 mg as compared to placebo on cardio -
pulmonary hemodynamics and disease 
severity in subjects with PH after LVAD implantation . 
• To evaluate the safety and tolerability of macitentan 10 mg in subjects with PH after LVAD implantation.  
Exploratory objectives 
• To explore the potential effect of macitentan 10 mg as 
compared to placebo on right ventricular function in 
subjects with PH after LVAD implantation.  
• To explore the potential effect of macitentan 10 mg as 
compared to placebo on selected clinical events in subjects 
with PH after LVAD implantation.  
• To explore the potential effect of macitentan 10 mg as 
compared to placebo on renal function as measured by [CONTACT_269383] (GFR) in subjects with PH after 
LVAD implantation.  
DESIGN  Prospective, multicenter, double -blind, randomized, 
placebo-controlled, parallel-group Phase 2 study. 
Macitentan / ACT-[ADDRESS_327792]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 20/103 Confidential  Doc No D-17.154 
 
PERIODS  Screening period:  Up to 90 days from LVAD implantation 
until Randomization. 
Treatment period:  From Randomization up to Week [ADDRESS_327793] an End-of- Treatment (EOT) visit within 7 days of study 
treatment discontinuation.   
Study treatment is defined as the dosing (intake) by [CONTACT_269384]-blind study drug (macitentan or placebo). 
Post-treatment safety follow -up period: Subjects who 
complete the treatment period as planned, i.e., full 12- week 
study period, and those who prematurely discontinue study 
treatment,  will enter a 30 -day safety follow -up period which 
ends with the End-of- Study (EOS) visit at least [ADDRESS_327794] visit.  
SITE(S)  
/ COUNTRY(IES)  Approximately 50 clinical sites in the [LOCATION_002].  
SUBJECTS / GROUPS  78 subjects in 2 groups, randomized in a 1:1 ratio by [CONTACT_269385]/Web Randomization System to macitentan 
10 mg or placebo. 
INCLUSION CRITERIA  
          1 Written Informed Consent prior to initiation of any 
study-mandated procedure.  
2 Males or females ≥ 18 years of age. 
3 Surgical implantation of LVAD within 90 days prior to 
Randomization. 
4 Hemodynamic evidence of PH on Baseline right heart 
catheterization (RHC) by [CONTACT_269386]. 
Baseline RHC is defined as the last he modynamic 
measurements after LVAD implantation and prior to the 
first dose of study treatment. PH is defined as:  
a) Mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg 
and 
b) Pulmonary artery wedge pressure (PAWP)  ≤ 18 mmHg  
and 
c) PVR > 3 Wood units.  
Macitentan / ACT-[ADDRESS_327795]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 21/103 Confidential  Doc No D-17.154 
 
INCLUSION CRITERIA  
(cont’d) 5 Stabilization of  the patient for 48 h prior to the Baseline 
RHC, defined as: 
a) No LVAD pump speed/flow rate changes and 
b) Stable dose of oral diuretics  and 
c) No intravenous (i.v.) inotropes or vasopressors and  
d) Patient able to ambulate . 
6 A woman of childbearing potential is eligi ble only if she 
has: 
a) A negative serum pregnancy test result during the 
Screening period (Visit 1) and Randomization (Visit 2) and  
b) Agreement to undertake monthly serum pregnancy tests 
during the study and up to 30 days after study treatment 
discontinuation and 
c) Agreement to use one of the methods of contraception / 
follow the contraception scheme described in 
Section 4.[ADDRESS_327796] be r andomized within 14 days of Baseline 
RHC. 
EXCLUSION CRITERIA  
           1 Documented severe obstructive lung disease defined as: 
forced expi[INVESTIGATOR_3741] 1 second / forced vital capacity (FEV
1/FVC) < 0.7 associated with FEV 1 < 50% of predicted 
value after bronchodil ator administration.  
2 Documented moderate to severe restrictive lung disease 
defined as: total lung capacity < 60% of predicted value. 
3 Documented pulmonary veno- occlusive disease.  
4 Patients undergoing dialysis.  
5 Hemoglobin < 8.5 g/dL at Randomization.  
6 Aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) > 3 × the upper limit of normal 
(ULN) at Randomization. 
7 Severe hepatic impairment, e.g., Child- Pugh Class C liver 
disease. 
8 Body weight < 40 kg at Randomization. 
9 Doppler mean blood pressure < 65 mm Hg at 
Randomization. 
10 GFR < 30 mL/min at Randomization. 
11 Pregnant, planning to become pregnant during the study 
period, or breastfeeding.  
Macitentan / ACT-[ADDRESS_327797]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 22/103 Confidential  Doc No D-17.154 
 
EXCLUSION CRITERIA (cont ’d) 
 12 Treatment with endothelin receptor antagonists (ERAs), 
phosphodiesterase- 5 (PDE5) inhibitors, i.v., subcutaneous 
(s.c.), or oral prostanoids, or guanylate cyclase stimulators 
within 7 days prior to Baseline RHC or study treatment  
initiation. 
13 Treatment with inhaled prostanoids (e.g., iloprost, 
epoprostenol) or nitric oxide within 24 h prior to Baseline 
RHC or study treatment initiation . 
14 Treatment with strong inducers of cytochrome P450 
isozyme 3A4 (CYP3A4) within 28 days prior to study 
treatment initiation  (e.g., carbamazepi[INVESTIGATOR_050], rifampi[INVESTIGATOR_2513], 
rifabutin, phenytoin and St. John’ s Wort).  
15 Treatment with strong inhibitors of CYP3A4 within 28 days 
prior to study treatment initiation  (e.g., ketoconazole, 
itraconazole, voriconazole, clarithromycin, telithromycin, 
nefazodone, ritonavir, saquinavir, boceprevir, telaprevir, 
iopi[INVESTIGATOR_054], fosamprenavir, darunavir, tipranavir, atazanavir, 
nelfinavir, amprenavir, and idinavir). 
16 Treatment with another investigational drug (planned, or 
taken) within 28 days prior to  study treatment initiation . 
17 Known hypersensitivity to ERAs, or to any of the study 
treatment excipi[INVESTIGATOR_840].  
18 Any condition that prevents compliance with the protocol or adherence to therapy.  
19 Known concomitant life -threatening disease with a life 
expectancy < 12 months. 
STUDY TREATMENTS  Investigational treatment  
Macitentan oral tablet, 10 mg once daily. Comparator and/or placebo Matching pl acebo, once daily.  
CONCOMITANT THERAPY  
    Allowed concomitant medication   
Oral and i.v. diuretics are allowed and may be adjusted during 
the treatment period.  (Treatment with oral diuretics is  allowed if ongoing at a stable 
dose for at least 48 h prior to the Baseline RHC .) 
 
Macitentan / ACT-[ADDRESS_327798]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 23/103 Confidential  Doc No D-17.154 
 
CONCOMITANT THERAPY  
(cont ’d) 
                 LVAD Flow Rate  Prohibited concomitant medications  
• Pulmonary arterial hypertension -specific therapy (ERAs, 
i.v., s.c., inhaled or oral prostanoids, PDE5 inhibitors, 
guanylate cyclase stimu lators). 
• Inhaled nitric oxide. 
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, 
voriconazole, clarithromycin, telithromycin, nefazodone, 
ritonavir,saquinavir, boceprevir, telaprevir, iopi[INVESTIGATOR_054], 
fosamprenavir, darunavir, tipranavir, atazanavir, nelfinavir, 
amprenavir, and idinavir) and strong inducers of CYP3A4 
(e.g., carbamazepi[INVESTIGATOR_050], rifampi[INVESTIGATOR_2513], rifabutin, phenytoin and 
St. John’s Wort). 
• Any investigational drug. 
Initiation of one of these prohibited medications will lead to 
premature discontinuation of study treatment . 
Allowed LVAD Flow Rate  
The LVAD pump speed/ flow rate may  be adjusted  during the 
treatment period  and during the Baseline RHC.  
(LVAD p ump speed/flow rate must be stable for at least 48  h 
prior to the Baseline RHC ). 
ENDPOINTS  
              Definitions  
Baseline is defined as the last value obtained prior to first dose 
of study treatment. Primary efficacy endpoint  
PVR ratio of Week 12 to Baseline. PVR is obtained by [CONTACT_269387]. 
Secondary efficacy endpo ints 
Change from Baseline to Week 12 in mean right atrial pressure, 
mPAP, PAWP, cardiac index (CI), total pulmonary resistance, 
and mixed venous oxygen saturation, all measured at rest. 
Change in NT-proBNP from Baseline to Week 12.  Change in WHO functiona l class from Baseline to Week 12.  
Macitentan / ACT-[ADDRESS_327799]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 24/103 Confidential  Doc No D-17.154 
 
ENDPOINTS  
(cont ’d) Exploratory efficacy endpoints  
Change in echocardiographic variables from Baseline to 
Week 12. These variables include: 
• 2D global RV longitudinal strain  
• RV sphericity index  
• RV end systolic area  
• RV end diastolic area  
• Tricuspid annular plane systolic excursion  
• Tricuspid peak annular velocity s’ 
• RV fractional area change  
• Tricuspid peak diastolic annular velocities e ’, a’ 
Time to first encounter of clinical events, from enrollment to 
Week 12. These clinical events include:   
• Hospi[INVESTIGATOR_15564] (HF)  
• Re-initiation of i.v. diuretics ≥ 48 h duration  
• Re-initiation of i.v. inotropes ≥ 48 h duration  
• Initiation of PDE5 inhibitors 
• Need for right ventricular assist device / total artificial heart  
• Need for renal replacement therapy  
• Death.  
Days in the hospi[INVESTIGATOR_269364]. Change in GFR from Baseline to Week 12. Safety endpoints  
1 Treatment -emergent adverse events (AEs) up to 30 days 
after study treatment  discontinuation. 
2 AEs leading to premature discontinuation of study 
treatment. 
3 Death up to 30 days after study treatment discontinuation. 
4 Treatment -emergent serious adverse events (SAEs) up to 
[ADDRESS_327800] (ALT and/or AST) 
abnormality (≥ 3 × ULN; ≥ 3 and < 5 × ULN; ≥ 5 and 
< 8 × ULN; ≥  8 × ULN) up to EOT. 
7 Occurrence of ALT and/or AST abnormality ≥ 3 × ULN 
associated with bilirubin ≥ 2 × ULN up to EOT . 
Macitentan / ACT-[ADDRESS_327801]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 25/103 Confidential  Doc No D-17.154 
 
8 Proportion of patients with treatment -emergent hemoglobin 
abnormality (< 10.0 g/dL, and < 8.0 g/dL) as compared to Baseline up to EOT. 
9 Treatment -emergent marked laboratory abnormalities up to 
EOT. 
ASSESSMENTS  Refer to the schedule of assessments in  Table 1. 
STATISTICAL METHODOLOGY  
                      Analysis sets  
The Screened Analysis Set includes all patients who were 
screened and received a  Screening number. 
The Safety Set (SS) includes all patients who received at least 
one dose of study drug in the double- blind treatment period. 
The Full Analysis Set (FAS) includes all patients randomized.  
The modified FAS includes all patients in the FAS that have received at least one dose of study drug in the treatment period 
and have a Baseline, and at least one post -Baseline, PVR 
measurement.  
The Per-Protocol Set (PPS) comprises all patients included in 
the modified FAS without major protocol deviations.  
Primary efficacy variable 
The primary efficacy variable is the PVR ratio of Week 12 to 
Baseline. 
Statistical hypotheses  
The null hypothesis is that the mean PVR ratio is the same in the macitentan and placebo groups. 
The alternative hypothesis is that the mean PVR ratio is lower 
in the macitentan group as compared to the placebo group. 
Type-I and -II errors and power  
The type I error (α) is set to 0.025 (one- sided), the type II error 
is set to 0.20 and the power to 80%. Sample size calculation  
There are no randomized trial data in this patient population. 
However, an integrated analysis of two bosentan studies, 
BENEFIT  (AC-052- 366) and EARLY (AC -052-364), the 
hemodynamic sub- study of SERAPHIN (AC-055- 302), and the 
recently completed  MERIT study (AC -055E201) of macitentan 
Macitentan / ACT-[ADDRESS_327802]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 26/103 Confidential  Doc No D-17.154 
 
STATISTICAL METHODOLOGY  
(cont ’d) in patients  with inoperable chronic thromboembolic pulmonary 
hypertension, suggest that the treatmen t group difference on 
PVR is around −0.28 on log scale  (ranged from  −0.45 to −0.17 
with 95% confidence interval: −0.35, −0.21) and that the within 
group standard deviation is around 0.40 (90% confidence 
interval: 0.38, 0.42) on log scale.  
Under assumptions of the treatment group difference −0.[ADDRESS_327803] deviation 0.41 on log scale, 
70 evaluable patients will be needed for 80% power ( 35 patients 
per group). Accounting for 10% non- evaluable patients, 
78 patients will need to be randomized. 
Primary analysis The primary analysis will be performed on the FAS. 
The Week 12 versus Baseline ratio in PVR will be 
log-transformed (base e) and analyzed using an analysis of 
covariance with a factor for treatment group and a covariate for Baseline log PVR. The treatment group differenc
e in mean 
change from Baseline (on log scale) and its 95% CI will be 
estimated based on the model. The geometric mean ratio (GMR; 
macitentan vs. placebo) and its 95% CI will be obtained by 
[CONTACT_151698]. The null hypothesis will be rejected if the entire 95% CI is below one. 
The treatment effect will be expressed as (GMR−1) × 100%, 
where a negative value indicates a reduction of PVR in the 
macitentan group as compared to the placebo group.  
If PVR cannot be calculated due to missing PAWP but mPAP and cardi
ac output are available for the same visit, PAWP will 
be imputed. In patients with a post -Baseline PVR measurement 
obtained before Week 12, the last post -Baseline PVR 
measurement will be carried forward.  If a patient has no 
post-Baseline PVR measurement, t he ratio of Week [ADDRESS_327804] Baseline 
PVR will be not evaluable and excluded from the analysis. 
  
Macitentan / ACT-[ADDRESS_327805]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017,  page 27/103 Confidential  Doc No D-17.154 
 
Secondary and exploratory analyses  
Secondary and explorator y efficacy variables will be analyzed 
o n  t h e  F A S  a t  α  = 0.025 (one -sided) using 95% confidence 
limits. No correction for multiple testing will be applied for 
these analyses.  
Safety endpoints  
Safety data including AEs and SAEs will be summarized using  
the SS. 
STUDY COMMITTEES A Steering Committee is involved in the study design and will 
be consulted prior to and during the study for relevant medical issues and study publications. 
An Independent Data Monitoring Committee (IDMC), with 
members representing the specialties of cardiology and 
biostatistics, has overall responsibility for safeguarding the 
interests of subjects by [CONTACT_269388], discontinuation, or completion of the study. The composition and operation of the IDMC is described 
in the IDMC charter.  
A Clinical Event Committee (CEC) is an independent 
committee appointed by [CONTACT_269389][INVESTIGATOR_269365]. This standardized assessment of HF admi
ssion events is 
expected to limit variability and potential for bias associated 
with site-based event(s). The composition and operation of the 
CEC is described in the CEC charter. 
A Core Hemodynamics Laboratory (CHL) has been appointed 
to review RHC tracin gs to allow for a standardized assessment 
of data quality. The RHC tracings data will be recorded by [CONTACT_269390] a CHL Case Report Form, entered into the study 
database, and analyzed for variability. Services of the CHL are 
governed by a CHL charter.  
Macitentan / ACT-[ADDRESS_327806]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 28/103 Confidential  Doc No D-17.154 
 
Table 1 Visit and assessment schedule 
 
PERIODS  Name [CONTACT_180551] -BLIND TREATMENT  FOLLOW -UP 
 Duration  Up to 90 days  12 Weeks   30 days 
VISITS  Number 1 2 3 4 5 U1, U2, etc.  6 
 Name [CONTACT_6674]1a Randomization1b Week 4 Week 8 Week 12 or EOT2  Unscheduled Visit3 EOS4 
 Time Day −90 to Day −1  Day 1 Day 28 
(± 7 days)  Day 56 
(± 7 days) Day 84 
(± 7 days) Any day between Days 
1 and 84 30 days (+ 7 days) 
after last dose  
Informed Consent X       
Eligibility  X       
Randomiz ation  X      
Demographics & baseline 
characteristics  X       
Medical history  X       
Medications  X X X X X X X 
Physical examination5 X    X X  
Vital signs, body weight , height 
and BMI6 X X   X X  
Screening laboratory tests  X7a X7a      
Central l aboratory tests   X7b X X X X X 
Contraception  check & Pregnancy 
test8 X X X X X X X 
RHC by [CONTACT_269391] X9a    X9b X9c  
Echocardiography   X10   X X11  
NT-proBNP  X   X X  
WHO functional c lass  X   X X  
Study treatment  dispensing/return   X X X X12 X  
AEs and SAEs13 X X X X X X X 
  
Macitentan / ACT-[ADDRESS_327807]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 29/[ADDRESS_327808] dose of study treatment or within 7 days  of study treatment  discontinuation if prior to Week12 (Day 84).  
3 Unscheduled V isits can be performed at any time during the study, as necessary, at the investigator’s discretion. Study specific procedure/assessments that are marked 
(X) may be performed during an Unscheduled V isit, and corresponding data will be collected in the eCRF.  
[ADDRESS_327809] be recorded on the Medical History eCRF page . Findings made after signing of informed 
consent, and which meet the definition of an AE [Section  10.1.1], must be recorded on the AE page of the eCRF.  
6 Height is only measured at Screening  (in cm). 
7a At the time of Screening, local lab oratory results may be used f or determination of subject status (e.g., guiding RHC decision-making). At the time of Randomization, 
local laboratory results will be used to determine subject eligibility.  
7b Central lab results must be collected and submitted once eligibility is confirmed and prior to Randomization. Laboratory testing includes hematology and blood 
chemistry . Additionally, NT proBNP, biomarkers and calculated GFR will be performed on Visits 2 and 5. 
8 For women of childbearing potential only.  Randomization (Visit  2) pregnancy test result must be negative prior to Randomization. 
9a  The last hemodynamic measurements after LVAD implantation and prior to the first dose of study treatment. Randomization must be within [ADDRESS_327810] RHC, the data should be entered as Week 12 or 
EOT RHC (see 9b). If the Unscheduled RHC is before the last (Week 12 or EOT) RHC, the data should be entered as Unscheduled  Visit.  
[ADDRESS_327811] be recorded in the eCRF.  
12 If study treatment discontinuation occurs prior to Week 12 (Day 84), record drug return as per standard procedure (e.g. , on the eCRF Study Drug Dispensing and 
Accountability form).  
13All AEs and SAEs that occur after signing the Informed Consent Form and up to [ADDRESS_327812] be reported in the eCRF.  
 
AE = adverse event; BMI = body mass index; eCRF = electronic case rep ort form; EOS = End -of-Study; EOT = End-of- Treatment; GFR = glomerular filtration rate; 
LVAD = left ventricular assist device; NT -proBNP = N -terminal prohormone of brain natriuretic peptide; SAE = serious adverse event; WHO = World Health 
Organization. 
  
Macitentan / ACT-[ADDRESS_327813]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 30/103 Confidential  Doc No D-17.154 
 
 PROTOCOL 
1 BACKGROUND  
1.1 Indication  
End-stage heart failure (HF) is a debilitating condition for which heart transplant offers 
the best treatment option, but the need for donor hearts greatly exceeds supply. This shortage of donor hearts underscores the need for alternative treatment options. Since the first approval by [CONTACT_2165] (FDA) of a left ventricular assist device (LVAD) as bridge to transplant in 1994 and as destination therapy (DT) in 2002, LVADs have become an increasingly frequent treatment option for patients with end-stage HF [Rommel 2014] . In patients with advanced HF, the use of continuous flow 
LVADs results in clinically meaningful survival benefits and improved quality of life [Rose 2002, Slaughter 2009].  
While LVADs improve left -sided hemodynamic variables, right ventricular failure (RVF) 
occurring after the implantation of LVADs is a major cause of morbidity and mortality [Patlolla 2013, Grant 2012]. Pre-operative right ventricular dysfunction often does not 
improve after left ventricular mechanical unloading and may even worsen. Persistently 
elevated pulmonary vascular resistance (PVR) is associated with RVF after LVAD implantation [Rommel 2014 ]. Patlolla et al suggest that LVADs cause geometrical and 
functional changes in the right ventricle  (RV) [Patlolla 2013]. The dynamic change in 
ventricular interdependence, ventriculo- arterial coupling, afterload and preload following 
LVAD insertion may determine RV compensation following LVAD. Patients with baseline dilated RV, decreased RV contractility, or severely increased stiffness may be particularly susceptible to ventriculo -arterial uncoupling and RVF after LVAD insertion.  
The indication of this study is pulmonary hypertension (PH) appearing, maintaining, or 
worsening after LVAD implantation. The diagnosis of PH is based on pulmonary hemodynamic criteria obtained via right heart catheterization (RHC), i.e., mean pulmonary arterial pressure (mPAP) ≥ [ADDRESS_327814] become a more frequent treatment choice for 
patients with end -stage HF. This is due to the improvement in the engineering design and 
reduction in size of these devices. For example, the US -based Interagency Registry for 
Mechanically Assisted C irculatory Support (INTERMACS) has over 12,000 LVADs in 
their database, of which 6000 were implanted since 2012 [ Kirklin 2014].  
While LVADs improve left- sided hemodynamic variables (e.g., increase cardiac output 
[CO], reduce pulmonary artery wedge pressure [PAWP]), RVF occurring after the 
Macitentan / ACT-[ADDRESS_327815]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 31/103 Confidential  Doc No D-17.154 
 
implantation of LVADs is a major cause of morbidity and mortality [Patlolla 2013, 
Grant 2012, Kukucka 2011b, Kormos 2010] . The incidence of RVF ranges from 9 –44%, 
depending on the definition of RVF used, the type of device used (pulsatile or continuous flow), the indication for LVAD support (bridge to transplantation, bridge to recovery, or DT) and finally, the baseline characteristics or comorbidities of the studied population [Patlolla 2013]. 
1.[ADDRESS_327816] device (RVAD) and inhaled pulmonary vasodilators. Post -operatively, 
the management of PH complicated with RVF in these patients includes the use of pulmonary vasodilators, changing the pump speed under echocardiography guidance and if refractory RVF, consideration of an RVAD implantation [ Patlolla 2013]. 
To date, the role of pulmonary vasodilators in LVAD patients with PH has only been investigated in small pi[INVESTIGATOR_7602]. Inhaled nitric oxide (iNO) decreased pulmonary arterial pressures and improved LVAD flow in a study in which [ADDRESS_327817] -operatively [Argenziano 1998 ]. These results, 
however, were not reproduced in two small studies in which LVAD patients were given iNO at [ADDRESS_327818]-operatively [Kukucka 2011a , Potapov 2011] . Antoniou et 
al examined the use of iloprost in [ADDRESS_327819]-LVAD insertion treated simultaneously with inotropes and iNO  [Antoniou 2012]. 
The authors reported a significant reduction in PVR, mPAP, PAWP, and an increase in LVAD flow post -combined inhaled therapy. 
In an open -label study of 26 LVAD recipi[INVESTIGATOR_840], sildenafil therapy plus LV AD support was 
more effective than LVAD alone in lowering PVR [Tedford 2008
]. Specifically, the 
average PVR in the sildenafil -treated group fell from 5.9 to 3 Wood units (WU) while the 
PVR in the LVAD recipi[INVESTIGATOR_269366] 1  WU. 
Klodell et al also investigated the role of sildenafil in LVAD patients with persistent PH 
[Klodell 2007 ]. In [ADDRESS_327820] -implantation of a continuous- flow LVAD resulting in significantly 
decreased PVR [Imamura 2013]. LaRue et al investigated 50  patients on bosentan in a 
Macitentan / ACT-[ADDRESS_327821]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 32/103 Confidential  Doc No D-17.154 
 
single center series; treated for a mean duration of 16.3 (±  12.1) months, including 
30 patients for greater than 1 year [LaRue 2013]. The study results showed the drug to be 
well tolerated in this patient cohort. In addition, at 6 -month follow -up there was 
right-sided decongestion with improvement in both the bilirubin and alkaline phosphatase 
levels. These studies were replicated in a follow -up single center retrospective study by 
[CONTACT_269392] [LaRue 2013]. In this cohort, consecutive patients with mean PA > 25 mmHg 
were treated with bosentan after LVAD implantation for a mean duration of 15.7 (± 12.4) 
months. Comparison of the baseline to 6- month follow -up data revealed laboratory 
evidence of decreased BNP, hepatic decongestion as well as improvement in 
echo-derived pulmonary  hemodynamics including PVR decrease of 1.[ADDRESS_327822] (LFT) 
abnormalities [LaRue 2013].  
The current International Society for  Heart and Lung Transplantation guidelines on 
mechanical circulatory support [Feldman 2013 ] suggest PH -specific therapi[INVESTIGATOR_269367]- intensive 
care unit post-operative period (Class IIb, Level of Evidence C). 
1.4 Endothelin -1 and pulmonary hypertension  
Endothelin- 1 (ET-1), a [ADDRESS_327823] potent vasoconstrictors 
and mitogens for smooth muscle, and contributes to increased vascular tone and 
proliferation in pulmonary vasculopathy [ Galiè 2004].  
There are [ADDRESS_327824] receptors for ET -1: endothelin receptor A (ET A) and endothelin 
receptor B (ET B). The [ADDRESS_327825] unique binding locations and affinities for the 
endothelin peptide [Benigni 1995, Massaki 1998 ]. The ET A receptors are expressed on 
pulmonary vascular smooth muscle cells, whereas ET B receptors are present both on 
pulmonary vascular endothelial cells and on smooth muscle cells.  When activated, the ET
A receptors located in pulmonary vascular smooth muscle cells 
mediate a potent vasoconstrictive response, and ET B receptors on endothelial  cells 
mediate vasodilatation via increased production of nitric oxide and prostacyclin [Hirata 1993, de Nucci 1988]. ET -1 is also known to be a potent mitogen, with the abil ity 
to induce cell proliferation in vascular smooth muscle cells. It has been shown that both the ET
A and ET B receptors mediate the mitogenic action of ET -1 [Clarke 1989, 
Chua 1992, Davie 2002, Sugawara 1996].  
Laboratory and clinical investigations have clearly shown that ET -1 is overexpressed in 
several forms of pulmonary vascular disease. ET -1 is likely a major factor in the 
vasodilator and vasoconstrictor imbalance, as well as in the abnormal pulmonary vascular remodeling present in the development and progression of PH of various etiologies [Stewart 1991, Giaid 1993].  
Macitentan / ACT-[ADDRESS_327826]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 33/[ADDRESS_327827], Asia and Latin America  for the treatment of 
pulmonary arterial hypertension (PAH).  
1.5.[ADDRESS_327828]. 
Macitentan showed dose- dependent efficacy in nonclinical models of hypertension and 
PH, and is approximately 10 times more potent than bosentan (Tracleer®). In nonclinical 
safety studies, no effects on normal physiological functions or electrocardiogram variables, including cardiac repolarization, were observed – with the exception of a 
decrease in arterial blood pressure (BP) observed in a cardi ovascular study in dogs. 
Macitentan has no genotoxic potential. In the pi[INVESTIGATOR_22735] [ADDRESS_327829] (ERA) class effect.  
More detailed information on macitentan can be found in the Investigator’s Brochure (IB) [Macitentan  IB]. 
1.5.2 Phase 1 results  
During the Phase 1 program, more than 200 healthy subjects and about 30 patients (with renal and hepatic impairment) were treated with macitentan. Macitentan was well tolerated in all studies. The most frequently reported adverse event (AE) wa s headache.  
More detailed information on macitentan can be found in the IB [ Macitentan  IB]. 
1.5.3 Phase 2 results  
Phase 2 studies were conducted in patients with mild -to-moderate essential hypertension, 
and in patients wi th idiopathic pulmonary fibrosis (IPF).  
A Phase 2 dose- finding study [Macitentan  IB] was conducted in patients with 
mild-to-moderate essential hypertension. In this study, treatment with the 10 mg dose of 
macitentan was associated with a statistically significant reduction (vs. placebo) from baseline to Week 8 in mean sitting diastolic blood pressure (DBP) at trough, which was the primary endpoint of the study. 
Macitentan / ACT-[ADDRESS_327830]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 34/103 Confidential  Doc No D-17.154 
 
In a Phase 2 study in patients with IPF [Raghu 2013] , the primary endpoint (change in 
forced vital capacity [FVC]) was not met, but it was shown that macitentan treatment with 10 mg dose was well tolerated.  More detailed information on macitentan can be found in the IB [ Macitentan  IB]. 
1.5.4 Phase 3 efficacy results in PAH  
Effectiveness was established in a long -term study in PAH patients with predominantly 
WHO functional class (FC) II–III symptoms treated for an average of 2 years [Pulido 2013] [Appendix 1] . Patients had idiopathic or heritable PAH (57%), PAH 
caused by [CONTACT_269393] (31%), and PAH caused by [CONTACT_269394] d shunts (8%) and were treated with macitentan monotherapy (36%) or in 
combination with phosphodiesterase -5 (PDE5) inhibitors (61%) or inhaled/oral 
prostanoids (5%).  
The trial demonstrated that macitentan 10 mg reduces the risk of morbidity/ mortality in patients with symptomatic PAH by 45% as compared to placebo of (hazard ratio 0.547, 97.5% confidence limits (CLs) 0.392–0.762, p < 0.0001).  The placebo -corrected mean change in 6 -minute walk distance (6MWD) from baseline to 
Month 6 showed an increase of 22.0 m (97.5% CLs 3.2, 40.8) with macitentan 10  mg 
versus placebo. Additionally, improvements in WHO FC from baseline to Month 6 were reported for 22.3% of patients in the macitentan 10 mg group, compared to 12.9% of patients in the placebo group. This translates into a 74% higher chance relative to placebo of WHO FC improvement in patients on the 10 mg dose (relative risk 1.74, 97.5% CLs 1.10, 2.74, p = 0.0063). The treatment effect of macitentan on WHO FC was maintained over time. 
The median change versus placebo in NT -proBNP from baseline to Month 6 was  
–160 fmol/mL (97.5% CLs –235, –95) with macitentan [ADDRESS_327831] of reduction in PVR after 
6 months of treatment with macitentan 10 mg was  36.5% (97.5% CLs 21.7, 49.2), The 
placebo-corrected median change in cardiac index (CI) (L/min/m 2) from baseline to 
Month 6 was 0.58 (97.5% CLs 0.28, 0.93) in the macitentan 10 mg group.  
More detailed information on macitentan can be found in the IB [ Macitentan  IB]. 
1.5.[ADDRESS_327832] of ERAs. The p rotocol, therefore, 
includes stringent requirements for pregnancy testing and reliable methods of contraception for female patients of childbearing potential.  
Macitentan / ACT-[ADDRESS_327833]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 35/103 Confidential  Doc No D-17.154 
 
In three placebo- controlled studies with macitentan (two Phase 2 studies in essential 
hypertensio n and IPF and one Phase 3 study in PAH), no significant imbalance in liver 
test elevations was observed across macitentan treatment groups and placebo. The proportions of patients with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) elevations > 3 × upper limit of the normal range (ULN) were 
similar across the treatment groups. Additionally, cases with ALT/AST > 3 × ULN and 
total bilirubin > 2 × ULN, suggesting Hy’ s Law, were reported with very similar 
incidences across macitentan and  placebo treatment groups. All of these events were 
characterized by [CONTACT_35250]; linked to the underlying disease or to concomitant disease or medications. Overall, these findings do not indicate that macitentan is associated with a definite hepat otoxicity signal. Patients with serum AST and/or ALT 
> 3 × ULN are excluded from the study, and monthly liver tests are mandatory during the study. Treatment with ERAs has been associated with increased incidence of edema, anemia and/or decreased hemoglobin [Abman 2009, O’Callaghan 2011] . Treatment with 
macitentan was associated with a dose- related reduction in hemoglobin levels, which was 
established within the first 3 months of treatment. Decreased hemoglobin levels tended to 
show recovery towards baseline after discontinuation of treatment. Higher incidences of anemia AEs were reported in a dose- related fashion in the patients treated with 
macitentan in comparison to those tr eated with placebo. Anemia required transfusion in 
some patients treated with macitentan. Patients with hemoglobin <  8.5 g/dL and who do 
not recover during the Screening period are excluded from the study. Monthly 
hemoglobin tests are mandatory during the study. The incidences of edema AEs were similar in the macitentan and placebo groups, although subgroup analyses indicated fluctuations in the incidence of edema, with no clear pattern according to treatment (macitentan versus placebo) or macitentan dose. Edema serious adverse events (SAEs) were uncommon with macitentan treatment and only 3 patients (2 on placebo and 1 on macitentan 10 mg) discontinued treatment due to an edema AE. Overall, there is no indication that edema represents a significant safety concern with macitentan therapy in PAH.  
Due to the vasodilatory effects of macitentan, effects on blood pressure might occur. In patients with normal blood pressure prior to initiation of macitentan treatment, there was a slightly higher incidence of AEs denoting hypotension, relative to placebo on macitentan. However, hypotension SAEs were reported less frequently on macitentan than on placebo, and only one macitentan- treated patient discontinued due to this AE. 
Hypotension AEs were predominantly reported f or female patients and there was no 
indication of an increased incidence in other potentially vulnerable subgroups, such as the elderly, or patients with renal function impairment at baseline.  
Macitentan / ACT-[ADDRESS_327834]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 36/103 Confidential  Doc No D-17.154 
 
Reductions from baseline in leukocyte and platelet counts may be observed with macitentan. In the AC -055-302 / SERAPHIN study, macitentan was associated with 
modest and non-dose- dependent decreases in mean leukocyte count from baseline to 
End-of-Treatment (EOT). A small proportion of PAH patients, in both placebo and 
macitentan groups, showed markedly reduced platelet counts, with or without bleeding complications, at some time during the study. Resolution during continued treatment with macitentan was observed, as well as absence of recurrence after treatment re -initiation, 
findings that make a specific, causal relationship to macitentan unlikely. In the AC -055-302 / SERAPHIN study, menstrual disorder AEs (mainly menorrhagia, 
metrorrhagia, and dysfunctional bleed) and ovarian cysts were reported at a low incidence over all, but more frequently on macitentan than placebo, in females of 
childbearing potential. None of the events led to discontinuation of study drug, there was no consistent drug -dose or drug -exposure pattern, and resolution of menstrual disorder s 
during ongoing treatment was reported in the majority of cases. Confounding factors were present in the majority of these cases. A causal relationship to macitentan remains uncertain. In clinical trials, a higher reporting rate of upper respi[INVESTIGATOR_6014],  but also 
bronchitis, was seen with macitentan versus placebo. It is likely that many such events may represent symptoms of congestion due to local vasodilatation (e.g., rhinitis), rather than actual infection. For the clinically more relevant lower respi[INVESTIGATOR_6014], especially pneumonia, there was no relevant difference between macitentan and placebo. In addition, there was a higher incidence of urinary tract infections and gastroenteritis in the patients who received macitentan treatment compared to those who received placebo. However, given that there was no imbalance in the incidence of these events that were reported as SAEs or that led to discontinuation of treatment, coupled with the fact that there was no increase in the reporting rate over time, these AEs were considered to be of limited clinical relevance.  
Macitentan has not been studied in PH post -LVAD implantation. Thus, a number of 
safeguards have been implemented in the current protocol, i.e., monthly follow -up of 
patients and ongoing safety and efficacy  data review by [CONTACT_269395] (IDMC).  
For detailed information on the efficacy and safety profile of macitentan in PAH and other indications, please refer to the most recent version of the macitentan IB [Macitentan  IB]. 
It is the investigator ’s responsibility to monitor the benefit -risk ratio of study treatment 
administration, as well as the degree of distress caused by [CONTACT_269396] / ACT-[ADDRESS_327835]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 37/[ADDRESS_327836] level, a nd to discontinue study treatment or the study if, on balance, 
he/she believes that continuation would be detrimental to the subjects’ well-being. 
1.[ADDRESS_327837] utility of bosentan and sildenafil as long-term therapy in reducing PVR, thus reducing risk of RVF [Argenziano 1998, 
Antoniou 2012].  
Macitentan is an ERA, currently approved for the treatment of PAH in the US. In the Phase 3 AC -055-302/SERAPHIN study, macitentan demonstrated efficacy in PAH by 
[CONTACT_180482]- term clinical outcomes, functional status and exercise capacity. Based on 
the aforementioned results with sildenafil and bosentan in PH after LVAD implantation, it is believed that macitentan could be an efficacious treatment for this patient population.  
The purpose of this study is to investigate the effect  of macitentan on cardiopulmonary 
hemodynamics as well as the safety and tolerability in patients with PH post- LVAD 
implantation in a randomized, placebo-controlled study setting. 
2 STUDY OBJECTIVES  
2.1 Primary objective(s) 
To evaluate the effect of macitentan [ADDRESS_327838] of macitentan 10 mg as compared to placebo on cardio -pulmonary 
hemodynamics and disease severity  in subjects with PH after LVAD implantation. 
To evaluate the safety and tolerability of macitentan 10 mg in subjects with PH after LVAD implantation. 
Macitentan / ACT-[ADDRESS_327839]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 38/[ADDRESS_327840] of macitentan 10 mg as compared to placebo on renal function as measured by [CONTACT_269397] (GFR) in subjects with PH after LVAD implantation.  
[ADDRESS_327841] -LVAD implantation will be randomized 
(1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally. The 
attrition rate is expected to be 10%, leaving [ADDRESS_327842] dose of study treatment, 
defined as mPAP ≥ [ADDRESS_327843] and PAWP ≤ 18 mmHg and PVR > [ADDRESS_327844] be considered stable for 48 h prior to the Baseline RHC. Stabili ty is defined 
as having no LVAD pump speed/flow rate changes, being on a stable dose of oral 
diuretics, receiving no intravenous (i.v.)  inotropes or vasopressors, and being able to 
ambulate, for [ADDRESS_327845] visit. 
The study consists of the following study periods: Screening period:  Commences immediately following LVAD implantation and ends 
with subject Randomiz ation (up to a maximum of 90 days after surgical implantation of 
Macitentan / ACT-[ADDRESS_327846]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 39/103 Confidential  Doc No D-17.154 
 
LVAD). The Screening visit is the date at which signature [CONTACT_269428] 
(ICF) is obtained prior to initiation of any study -mandated procedure s. Screening and 
Randomization visits may be c onducted on the same day  provided that eligibility is 
confirmed and all study-mandated  procedures are completed prior to Randomization. 
Treatment period:  Study treatment is defined as the dosing (intake) by [CONTACT_269398]-blind study drug (macitentan or placebo). The treatment period starts immediately 
after Randomization with the first dose of study drug at the end of Visit 2 (Day 1 of 
study) and ends with EOT on the day of the last dose of study drug (scheduled Day 84, Week 12), or earlier in case of premature discontinuation of study treatment.  Subjects who prematurely discontinue study treatment  must have an EOT visit within 
[ADDRESS_327847]-treatment safety follow -up period:  Subjects who complete the study treatment as 
planned, i.e., a full 12- week study period, and those who prematurely discontinue study 
treatment,  will enter a 30 -day safety follow -up period, which ends with the End-of-Study 
(EOS) visit at least [ADDRESS_327848] during the treatment and follow -up 
periods [see Table 1]. 
For an individual subject, the study has ended once the EOT has been performed and the 
30-day safety follow- up is complete (EOS).  
The study is considered complete when all subjects have ended as detailed above.  
Study Duration:  Subject participation in the study will be up to 90 days ( Screening 
period) + 12 weeks (double -blinded treatmen t period) + 30 days (safety follow -up 
period). The overall study design is depi[INVESTIGATOR_6517] 1.  
Macitentan / ACT-[ADDRESS_327849]-LVAD implantation 
Protocol AC- 055-205 , SOPRANO 
Version 3 10 March 2017, page 40/103 Confidential Doc No D-17.154 
 Figure 1 Study design 
 
* Subjects who complete the study as pl anned, i.e., full 12-week study period and those who prematurely discontinue 
study treatment will enter a 30-day safety follow-up period, which ends with the EOS vis it at least 30 days after the 
permanent discontinuation of study treatment.  
EOT = End-of-Treatment; EOS = End- of-Study, LVAD = left ve ntricular assist devi ce; RHC = right heart 
catheterization. 
3.[ADDRESS_327850]-LVAD implantation population is a lim itation. Such limitation stems from the 
inability to differentiate between the mechan ical unloading effects of the LVAD, and at Placebo
Macitentan 10  mg      
  
        84 days  30 days 
  
   EOT  
  RHC  
 EOS SCREENING 
PERIOD 
LVAD to Randomization   
≤90 days 
LVAD 
Implantation Randomization  
Visit DOUBLE‐BLIND 
TREATMENT  PERIOD FOLLOW‐UP PERIOD*  
        ≤ 14 days  
Baseline  
    RHC 
Macitentan / ACT-[ADDRESS_327851]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 41/[ADDRESS_327852] are of sufficient magnitude to justify the inclusion of a placebo control group [Wright 2009] . Most 
importantly, HF patients with “fixed” PH have been reported to demonstrate a m arked 
reduction in pulmonary pressures at 6 months with LVAD therapy alone [Mikus 2011], 
which strongly suggests that a placebo arm is greatly needed to capture the true effects of the study drug rather than those of the LVAD itself. As most of the benefit from pulmonary vasodilators is likely to exist in patients with persistently elevated PVR and/or RV dysfunction after LVAD implantation, the need exists to evaluate post -LVAD 
hemodynamics for appropriate patient selec tion [LaRue 2015] . Hence, the present study 
aims to utilize post- LVAD hemodynamics as Baseline variables for a planned 
comparison with 12-week hemodynamics.  Treatment with ERAs has been associated with increased incidence of edema, anemia and/or decreased hemoglobin as well as LFT abnormalities. From three placebo-controlled studies with macitentan, involving 863 patients on macitentan and 
370 patients on placebo, no significant imbalance in LFT elevations was observed across 
macitentan treatment groups (any dose) and placebo. However, due to the underlying disease in this patient population that increases the likelihood of safety events, a placebo arm is the only definitive way to draw (or rule out) an association betw een the use of the 
study treatment and those potential safety events. 
3.[ADDRESS_327853] into the study. The composition and operation of the IDMC is described 
in the IDMC charter.  
A Clinical Event Committee (CEC) has been appointed by [CONTACT_269399][INVESTIGATOR_269368] (in a blinded fashion), so as to allow for a standardized assessment of HF admission events, limiting variability and potential biases associated with site- based event(s). The Committee is governed by a 
Clinical Endpoints Committee charter.  
Macitentan / ACT-[ADDRESS_327854]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 42/103 Confidential  Doc No D-17.154 
 
A Core Hemodynamics  Laboratory (CHL) has been appointed by [CONTACT_269400], so as to allow for a standardized assessment of data quality. The RHC tracings data will be recorded by [CONTACT_269401] a CHL eCRF , entered into the study 
database, and analyzed for variability. Services of the CHL will be governed by a charter. 
[ADDRESS_327855] be consid ered 
clinically stable.  
4.2 Rationale for the selection of the study population  
The primary objective of the study is to demonstrate a reduction in PVR versus Baseline with macitentan treatment as compared to placebo. Thus, patients need to present with elevated PVR (>  3 WU). Patients need to present with PAWP ≤  18 mmHg to rule out that 
their elevated PVR and mPAP is due to left -sided dysfunction. 
The absence of restriction on WHO FC and 6MWD will permit patients with severely symptomatic PH to be enrolled. Patients with h emoglobin < 8.5 g/dL, or AST and/or ALT > 3 × ULN, and who do not 
recover during the Screening period are excluded. Such patients are at increased risk of 
premature discontinuation and would impact on the study’ s ability to achieve its primary 
objective [see Section  1.5.5].  
As there is limited data on macitentan in pediatric PAH, subjects under the age of [ADDRESS_327856]: 1. Written Informed Consent prior to initiation of any study-mandated procedure(s). 
2. Males or females ≥ [ADDRESS_327857] dose of study treatment. PH is defined as:  
a.  mPAP ≥ 25 mmHg and  
b.  PAWP ≤ 18 mmHg and  
c. PVR > 3 WU.  
Macitentan / ACT-[ADDRESS_327858]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 43/103 Confidential  Doc No D-17.154 
 
5. Stabilization of the patient for 48 h prior to the Baseline RHC, defined as: 
a. No LVAD pump speed/flow rate changes and 
b. Stable dose of oral diuretics and 
c. No i.v. inotropes or vasopressors and 
d. Patient able to ambulate.  
6. A woman of childbearing potential [see definition in Section 4.5.1] is eligible only 
if the following applies: 
a. A negative serum pregnancy test result during the Screening period (Visit 1) and Randomization (Visit 2)  and 
b. Agreement to undertake monthly serum pregnancy tests during the study and up to 30 days after study treatment discontinuation  and 
c. Agreement to use one of the methods of contraception / follow the contraception scheme described in Section  4.[ADDRESS_327859]:  
1. Documented severe obstructive lung disease defined as: forced expi[INVESTIGATOR_3741] 1 second / forced vital capacity (FEV
1/FVC) < 0.7 associated with FEV 1 < 50% 
of predicted value after bronchodilator administration.  
2. Documented moderate to severe restrictive lung disease defined as: total lung capacity < 60% of predicted value. 
3. Documented pulmonary veno- occlusive disease.  
4. Patients undergoing dialysis. 
5. Hemoglobin < 8.5 g/dL at Randomization. 
6. AST or ALT > 3 × ULN at Randomization. 
7. Severe hepatic impairment, e.g., Child -Pugh Class C liver disease.  
8. Body weight < 40 kg at Randomization. 
9. Doppler mean blood pressure < 65 mmHg at Randomization. 
10. GFR < 30 mL/min at Randomization. 
11. Pregnant, planning to become pregnant during the study period, or breastfeeding. 
12. Treatment with ERAs, PDE5 inhibitors, i.v., subcutaneous (s.c.) or oral prostanoids, or guanylate cyclase stimulators within 7 days prior to Baseline RHC or study treatment  initiation . 
13. Treatment with inhaled prostanoids (e.g., iloprost, epoprostenol) or nitric oxide within 24 h prior to Baseline RHC or study treatment  initiation . 
Macitentan / ACT-[ADDRESS_327860]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 44/103 Confidential  Doc No D-17.154 
 
14. Treatment with strong inducers of cytochrome P450 isozyme 3A4 (CYP3A4) within 28 days prior to study treatment initiation (e.g., carbamazepi[INVESTIGATOR_050], rifampi[INVESTIGATOR_2513], rifabutin, phenytoin and St. John’ s Wort).  
15. Treatment with strong inhibitors of CYP3A4 within 28 days prior to study initiation (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin,  nefazodone, ritonavir, saquinavir, boceprevir, telaprevir, iopi[INVESTIGATOR_054], 
fosamprenavir, darunavir, tipranavir, atazanavir, nelfinavir, amprenavir, and idinavir). 
16. Treatment with another investigational drug (planned, or taken) within 28 days 
prior to study treatment initiation . 
17. Known hypersensitivity to ERAs , or to any of the study treatment excipi[INVESTIGATOR_840].  
18. Any condition that prevents compliance with the protocol or adherence to therapy.  
19. Known concomitant life- threatening disease with a life expectancy < [ADDRESS_327861] one of the following criteria:  
• Previous bilateral salpi[INVESTIGATOR_1656], bilateral salpi[INVESTIGATOR_8936] -oophorectomy or hysterectomy. 
• Premature ovarian failure confirmed by a specialist.  
• Pre-pubescence
2, XY genotype, Turner syndrome, uterine agenesis. 
• Post-menopausal, defined as 12 consecutive months with no menses without an 
alternative medical cause (Internationa l Council for  Harmonisation [ICH] M3 
definition).  
                                                 
2 Childbearing potential status and pregnancy status will be assessed at each visit and recorded in the electronic case 
report form (eCRF).  
Macitentan / ACT-[ADDRESS_327862]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 45/[ADDRESS_327863] use a reliable method of contraception. The use of one of the following options is regarded as reliable contraception:  Option [ADDRESS_327864]:  One method from this 
list:  One method from this list:   One method from this list:  
Standard intrauterine   Estrogen and   Diaphragm with   Partner’s vasectomy  
device (IUD) (Copper 
T380A IUD)   progestero ne oral 
contraceptives ( “the   spermicide  
Cervical cap with   PLUS one method from this 
list: 
Intrauterine system   Pi[INVESTIGATOR_4382]”)  spermicide   Male condom  
(LNg 20IUS: progesterone 
IUS)  
Estrogen and progesterone   PLUS one method from this 
list:  Diaphragm with  spermicide  
Progesterone implant   transdermal patch   Male condom   Cervical cap with  
Tubal sterilization   Vaginal ring     spermicide  
  Progesterone injection     Estrogen and progesterone 
oral contraceptives  
  PLUS one method from 
this list:    (“the pi[INVESTIGATOR_4382]”) 
  Male condom  
Diaphragm with spermicide 
Cervical cap with 
spermicide     Estrogen and progesterone 
transdermal patch  
Vaginal ring  
Progesterone injection 
 
Macitentan / ACT-[ADDRESS_327865]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 46/103 Confidential  Doc No D-17.154 
 
 4.6 Medical history  
Relevant medical history  either previous to or ongoing at time of Randomization 
(Visit 2), as defined below, must be recorded in the eCRF: 
• Chronic medical conditions and acute medical conditions within the past 6 months (e.g., anemia, hepatitis C infection, HIV infection, obstructive or restrictive lung disease, hypertension, renal disease)  
• Any previous life-threatening conditions, including date (e.g., myocardial infarction). 
5 TREATMENTS  
5.1 Study treatment  
Treatment in this study is double -blind, and comprises investigational treatment 
(i.e., active drug  macitentan)  or matching placebo administered orally once daily. Up- or 
down-titration does not apply. 5.1.1 Investigational treatment: description and rationale  
The investigational treatment is macitentan at the approved dose for PAH of 10 mg and is administered orally and at a frequency of once daily.  
5.1.2 Comparator(s) and/or matching placebo: description and rationale 
Matching placebo is administered orally and also once daily. Rationale for the use of a placebo arm is provided in Section 3.[ADDRESS_327866] at the clinical site during 
Randomization (Visit 2), and only after : successful completion of the ICF procedure, 
completion of all Screening/Randomization assessments, and confirmation that the 
patient meets all study eligibility criteria.  
Thereafter, one tablet (macitentan 10 mg or matching placebo) must be taken orally every morning irrespective of food intake. If a morning dose is missed, the next dose must be taken at the  next scheduled morning time point (i.e., do not take one tablet in the evening 
and then one tablet the next morning). Two tablets must never be taken on the same day. At all subsequent visits, study treatment  must be taken before any study procedures are 
performed. If a dose is not taken in the morning prior to arrival for the clinic visit, the next dose can be administered at the time of the clinic visit and prior to any study- related 
assessments.  
Macitentan / ACT-[ADDRESS_327867]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 47/103 Confidential  Doc No D-17.154 
 
 5.1.4 Treatment assignment  
Eligible subjects will be randomized in a 1:1 ratio to either macitentan 10 mg or matching 
placebo. At Visit 1 (Screening), all screened subjects will be assigned a study -specific 
subject number by [CONTACT_180488]/Web Response System (IxRS) provider. Details are provided in the IxRS manual. At Visit 2 (Randomization), and after having confirmed the eligibility of the subject and prior to the start of study treatment , the 
investigator/delegate contacts the IxRS to randomize the subject. The IxRS assigns a Randomization number to the subject, and assigns the treatment bottle number which 
matches the treatment arm assigned by [CONTACT_269402]. The bottle with this unique number is then dispensed to the subject and the first dose is administered.  
The Randomiz ation list is generated by [CONTACT_180491] 
(CRO) and kept strictly confidential.  
5.1.[ADDRESS_327868].  
5.1.6 Unblinding  
[IP_ADDRESS] Unblinding for final analyses  
Full Randomization information will be made available for internal Actelion data 
analysis only after database closure , and in accordance with Actelion standard operating 
procedures (SOPs).  
[IP_ADDRESS] Unbli nding  
The IDMC has overall responsibility for safeguarding the interests of subjects by [CONTACT_269388], discontinuation or completion of the study. The process for IDMC review of unblinded data is defined in the 
IDMC charter.  
Macitentan / ACT-[ADDRESS_327869]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 48/103 Confidential  Doc No D-17.154 
 
 [IP_ADDRESS] Unblinding for S[LOCATION_003]Rs  
When a suspected unexpected serious adverse reaction (S[LOCATION_003]R) occurs for a subject participating in the study, Actelion Global Drug Safety will request the unblinding of the treatment assignment. The Randomization code will not be communicated to the site staff 
or to the Actelion study team; unblinded S[LOCATION_003]R information will be anonymized and provided to Actelion Global Drug Safety, respective health authorities and Institutional Review Boards / Independent Ethics Comm ittees (IRBs/IECs) only. S[LOCATION_003]Rs will be 
reported to investigators in a blinded fashion. [IP_ADDRESS] Emergency procedure for unblinding  
The investigator, study staff and sponsor staff must remain blinded to the subject ’s 
treatment assignment. The identity of the study treatment may be revealed only if the 
subject experiences a medical event, the management of which would require knowledge of the blinded treatment assignment. In this case, the investigator can receive the unblinded R andomization code for study treatment  allocation through the IxRS. In these 
situations, the decision to unblind resides solely with the investigator. Whenever it is possible and if it does not interfere with (or does not delay) any decision in the best interest of the subject, the investigator  is invited to discuss the intended code break with 
Actelion. 
The occurrence of any code break during the study must be clearly justified and explained by [CONTACT_093]. In all cases, Actelion must be informed as soon as possible before or after the cod e break. 
The circumstances leading to the code break must be documented in the site study file and eCRF.  
5.1.7 Study treatment supply  
Manufacture, labeling, packaging and supply of study treatment s will be  conducted 
according to Good Manufacturing Practice (GMP) , Good Clinical Practice (GCP ) and 
any local or national regulatory requirements . 
All treatment supplies are to be used only in accordance with this protocol, and not for any other purpose. [IP_ADDRESS] Study treatment packaging and labeling 
[IP_ADDRESS].1 Study treatment packaging 
Study treatment is provided as tablets and supplied in childproof bottles. 
Macitentan / ACT-[ADDRESS_327870]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 49/103 Confidential  Doc No D-17.154 
 
 [IP_ADDRESS].[ADDRESS_327871] be removed and attached to the Study Treatment  
Dispensing Log. [IP_ADDRESS] Study treatment distribution and storage  
Treatmen t supplies must be kept in an appropriate, secure area and stored according to 
the conditions specified on the medication labels. The investigator is responsible for the safe and proper handling and storage at the investigational site and that the study 
treatment  is administered only to patients enrolled in the study and in accordance with the 
protocol. [IP_ADDRESS].1 Study treatment distribution 
The study centers will be supplied with study treatment  according to the centers ’ needs, 
depending on the rate of subject enrollment. Each center will have an individual stock of study treatment , which will be re -supplied continuously as soon as a predefined minimum 
level of study treatment has been reached.  
[IP_ADDRESS].[ADDRESS_327872], the investigator, or another duly designated person as specified on the Delegation of Authority (DoA) form. The subject must be educated on the proper study trea tment storage conditions at home.  
The study treatment  must be stored below 30 °C (86  °F). Keep the bottle tightly closed to 
protect from moisture.  Unopened, sealed medication bottles may be stored in the 
refrigerator (above +2 ºC [36  ºF]). Storage below  +2 ºC [36 ºF] (e.g., in the freezer) is not 
permitted . Opened bottles of study drug must not be stored in the refrigerator or freezer.  
A temperature log must be maintained and temperature control should occur at least on a weekly basis at the site. Actelion  will provide a temperature log; however, the use of the 
log is not mandatory if the site has an acceptable means of recording the temperature. Any temperature recording system routinely used at site is acceptable as long as all required information is included and certification of calibration is provided. If the temperature is captured electronically, a print -out should be made available to the clinical 
research associate (CRA) during each on -site visit for filing in the investigator site file 
(ISF).  
Macitentan / ACT-[ADDRESS_327873]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 50/[ADDRESS_327874] be reported to the CRA, preferably in writing and with supporting documentation (e.g., copy of the temperature log showing data for all excursion days). The CRA should immediately contact [CONTACT_180492]. The affected study 
treatment will not be used (e.g., it will be segregated physically at the study center) until 
confirmation from Actelion is obtained that its use is safe. If the temperature deviation is outside of the acceptable limit, the study treatment  is kept segregated at the study center, 
and returned to Actelion following internal study treatment  return processes. New study 
treatment supplies will be provided to the study center.  Site temperature deviations correspondence must be kept in the ISF.  
[IP_ADDRESS] Study treatment dispensing  
Study treatment  can only be dispensed by [CONTACT_269403]. The subjects will receive the study treatment  (one childproof bottle containing 36 tablets 
each) at Visit 2 (Randomization), Visit 3 (Week 4), and Visit 4 (Week 8) to cover the treatment period up to the EOT (Week 12) visit. Subjects are asked to return all used, partially used, and unused study treatment bottles at the Week 4, 8, and 12 visits. The protocol -mandated study treatment  dispensing/return procedures may not be altered 
without prior written approval from Actelion. An accurate record of the date and amount of study treatment dispensed to each subject m ust be available for inspection at any time.  
Once a subject has been randomized and study treatment  assigned, the corresponding 
bottle must not be used for another subject. If a subject has been dispensed a bottle in error (one that has not been allocated  yet to another subject), the IxRS helpdesk and study 
monitor / CRA must immediately be contact[INVESTIGATOR_530].  At the time study treatment  is distributed, the subject should be educated on the proper 
timing of dosing and the proper storage conditions of study treatment at home 
[see Section [IP_ADDRESS].2].  
[IP_ADDRESS] Study treatment return and destruction  
The site must record the amount of study treatment  received, dispensed, used, lost and 
returned during the study. On an ongoing basis and/or on termination of the study, the monitor will collect used and unused study treatment bottles, which will be sent to the warehouse, where Actelion or a 
sponsor delegate will check treatment reconciliation. In certain circumstances, used and unused tre atment bottles may be destroyed at the site once treatment accountability is 
Macitentan / ACT-[ADDRESS_327875]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 51/103 Confidential  Doc No D-17.154 
 
 finalized and has been checked by [CONTACT_269404], and written permission for destruction has been obtained from Actelion. 5.1.8 Study treatment accountability and compliance  with study treatment  
[IP_ADDRESS] Study treatment accountability  
The inventory of study treatment  dispensed and returned (i.e., study treatment  
accountability) must be performed by [CONTACT_269405]. It is recorded on the IMP dispensing and 
accountability log and in the eCRF and checked by [CONTACT_215232]. The study treatment accountability log in the eCRF will include at least 
the following information for each study treatment unit  dispensed to the subject: 
• Dispensed bottle number 
• Date dispensed / number of tablets dispensed  
• Date returned  / number of tablets  returned. 
All study treatment  supplies, including partially used or empty bottles must be retained a t 
the site for review by [CONTACT_2689]. If the subject forgets to bring the remaining study treatment  to a study visit, he/she must 
be instructed to not take any tablet/capsules from the remaining study treatment , and to 
bring it at the next visit.  
[IP_ADDRESS] Study treatment compliance  
Study treatment  compliance is based on study treatment  accountability, as per formula 
below: Compliance = [(number of tablets provided to subject - number of tablets returned) / 
total number of tablets that should have been taken during the p eriod] 
× 100 
During the study, and at each visit, compliance is expected to be between 80% and 120%. The investigator must check the reasons for any non- compliance with the subject and 
discuss actions to be taken to avoid re- occurrence at the next visit.  
5.1.9 Study treatment dose adjustments and interruptions  
Study treatment  may be temporarily interrupted only in response to an AE, a diagnostic 
or therapeutic procedure, a laboratory abnormality, or for administrative reasons. Study-specific criteria for interrup tion of study treatment are described in Section  5.1.11. 
Macitentan / ACT-[ADDRESS_327876]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 52/[ADDRESS_327877] for any reason, she/he must 
immediately inform the investigator.  
Interruptions of study treatment  should be kept as short as possible. If treatment is 
stopped for more than [ADDRESS_327878] be permanently discontinued [see Section  5.1.11]. 
Study treatment dose errors/interruptions must be recorded in the eCRF. 5.1.[ADDRESS_327879] has the right to prematurely discontinue study treatment  at any time by 
[CONTACT_269406], or by [CONTACT_269407] l from any further participation in 
the study [i.e., premature withdrawal from the study, see Section 9.2].  
The investigator should discontinue study treatment  for a given subject if, on balance, 
he/she believes that continued administration would be contrary to the best interests of 
the subject.  
Study treatment  may be discontinued in response to an AE, lack of efficacy (including 
disease progression, treatment failure, worsening of subject ’s condition), a protoc ol 
deviation (including eligibility failure, non- compliance with study requirements), a 
diagnostic or therapeutic procedure, a laboratory abnormality, or for administrative reasons.  
A subject ’s prior enrollment in an LVAD device study does not constitute eligibility 
failure. Additionally, simultaneous observational or non -interventional clinical trials 
(limited to blood sample collection) do not constitute basis for premature discontinuation of study treatment.  
Study-specific criteria for discontinuation of study treatment  are described in 
Section 5.1.11. A subject who prematurely discontinues study treatment  is NOT considered as withdrawn 
from the study, and will be followed up until EOS or [ADDRESS_327880] ’s consent for this limited participation in the 
study has not been withdrawn. 
A subject who prematurely discontinues study treatment and withdraws consent to 
participate in any further study assessments is considered as withdrawn from the study. 
Macitentan / ACT-[ADDRESS_327881]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 53/[ADDRESS_327882] to follow -up are also considered as withdrawn from the 
study. Withdrawal from the study and follow -up medical care of subjects withdrawn from 
the study are described in Section  9.2 and Section 9.4, respectively. 
5.1.11 Study-specific criteria for interruption / premature discontinuation of study 
treatment  A) Pregnancy 
If a female subject becomes pregnant while on study treatment , study treatment  must be 
discontinued immediately, and a Pregnancy Form must be completed [see Section 10.3].  
B) Liver aminotransferases abnormalities  
For abnormal laboratory  results ear ly in the study ’s Screening period (e.g., high ALT or 
AST), the patient should be monitored, provided with appropriate treatment , and 
reassessed throughout the Screening period (90 days from LVAD implantation ) for 
eligibility.  
Interruption of study treatme nt 
Study treatment  must be interrupted in the following cases:  
• Aminotransferases (i.e., ALT and/or AST) ≥ 3 and ≤ 8 × ULN  
In such a case, a re- test of aminotransferases (ALT and AST), total and direct bilirubin, 
and alkaline phosphatase must be performed within one week. If AST and/or ALT elevation is confirmed, aminotransferases, total and direct bilirubin, and alkaline phosphatase levels must continue to be monitored weekly until values return to pre-treatment levels, or within normal ranges. If the amin otransferase values return to 
pre-treatment levels or within normal ranges, reintroduction of study treatment  can be 
considered. Interruptions must be for less than 2 consecutive weeks; longer interruptions must lead to permanent discontinuation of study t reatment.  
Reintroduction of study treatment  after treatment interruption should only be considered 
if the potential benefits of treatment with macitentan outweigh the potential risks, and when liver aminotransferase values are within pre -treatment levels or within normal 
ranges. The advice of a hepatologist is recommended. Local lab oratories can be used for 
determination of subject status. However, a central lab oratory specimen must also be 
collected and submitted prior to reintroduction of study treatment. Liver aminotransferase levels must then be checked within 3 days after reintroduction, again after a further 2 weeks, and thereafter according to the recommendations above (i.e., at monthly intervals).  Specimens should be collected and submitted to the c entral 
laboratory as Unscheduled V isits. 
Macitentan / ACT-[ADDRESS_327883]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 54/[ADDRESS_327884] be stopped and its reintroduction is not to be considered in the 
following cases: • Aminotransferases > 8 × ULN  
• Aminotransferases ≥ 3 × ULN and associated clinical symptoms of liver injury, e.g., nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu like syndrome (arthralgia, myalgia, fever)  
• Aminotransferases ≥ 3 × ULN and associated in crease in total bilirubin ≥ 2 ×ULN. 
In such cases, aminotransferases, total and direct bilirubin, and alkaline phosphatase levels must be monitored weekly after study treatment  discontinuation until values return 
to pre-treatment levels, or within normal ranges.  
Other diagnoses (e.g., viral hepatitis, mononucleosis, toxoplasmosis, cytomegalovirus) and/or etiologies (e.g., acetaminophen- related liver toxicity) should be considered and 
ruled out by [CONTACT_180495]. All liver aminotransferases  abnormalities leading to study treatment  interruption or 
discontinuation must be recorded as AEs [see Section  10]. 
C) Hemoglobin abnormalities 
For abnormal laboratory results early in the study ’s Screening peri od (e.g. low 
hemoglobin), the patient should be monitored, appropriate treatment provided, and reassessed throughout the Screening period ( 90 days from LVAD implantation ) for 
eligibility.  
In case of hemoglobin decrease from Baseline* of > 2.0 g/dL, a re -test must be 
performed within 10 days, with additional laboratory evaluations that may include, but are not limited to, any of the following:  • Red blood cell cellular indices (mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration), peripheral blood smear, reticulocyte count, iron status (iron level, serum ferritin, total iron binding capacity, transferrin saturation), lactate dehydrogenase, indirect bilirubin.  
Study treatment  should be temporarily interrupted if clinically mandated based on the 
investigator’s judgment, or in any of the following situations: • A decrease in hemoglobin to < 6.5 g/dL,  
• A decrease in hemoglobin from Baseline* of > 5.0 g/dL,  
Macitentan / ACT-[ADDRESS_327885]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 55/103 Confidential  Doc No D-17.154 
 
 • The need for transfusion.  
Reintroduction of study medication may be considered if hemoglobin recovery, defined as a return of hemoglobin above the lower limit of the normal range or if it returns to a value close to that at Baseline.   
Interruption of study medication must not last longer than 2 consecutive weeks; longer interruption must lead to permanent discontinuation of study treatment.  Local lab oratories can be used for determination of subject status. However, a central 
laboratory specimen must also be collected and submitted prior to reintroduction of study 
treatment. 
*Baseline hemoglobin: last value obtained prior to first dose of study treatment.  D) Initiation of a prohibited concomitant medication  
Study treatment must be permanently discontinued if a prohibited concomitant medication is initiated. Prohibited concomitant medications are listed in Section  5.2.4.  
E) Clinical evidence of worsening PH or HF  
Study treatment  may be discontinued if the study subject demonstrates signs and 
symptoms of progressive HF reflecting worsening PH and RVF. Examples include, but are not limited to, the need for RV support pharmacologically with inotropes or mechanically with the implantation of RVAD, the development of diuretics resistance, objective evidence of declining RV function on echocardiography, evidence of increased PVR and/or decreased CO on RHC, and the need for escalation of PH therapi[INVESTIGATOR_014] (as covered in D). The decision to discontinue the study treatment  is based upon the clinical 
judgment and discretion of the principal investigator (PI) and is not limited to the 
examples listed above but will be documented in the eCRF.  
F) Cardiac transplantation  
Study treatment  must be permanently discontinued if a subject becomes a recipi[INVESTIGATOR_22874] a 
cardiac transplant. RHC obtained prior to cardiac transp lantation, to define the subject 
candidacy, must be captured as EOT RHC.  In case of premature study treatment  discontinuation, all EOT assessments, especially 
RHC, should be performed as detailed per EOT visit.  
Macitentan / ACT-[ADDRESS_327886]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 56/[ADDRESS_327887] administration of study treatment  up to Week 12 or earlier in case of 
premature discontinuation of study treatment. 5.2.2 Reporting of previous/concomitant therapy in the eCRF  
The use of all concomitant therapy (including contraceptives and traditional and alternative medicines, i.e., plant -, animal-, or mineral -based medicines) will be recorded 
in the eCRF. Previous therapy must be recorded in the eCRF if discontinued less than 28 days prior to Randomization. The generic name, start/end dates of administration (as 
well as whether it was ongoing at start of treatment and/or EOS), route, dose, and indication will be record ed in the eCRF. 
Hormonal contraceptives will be recorded on the contraception page of the eCRF.  5.2.3 Allowed concomitant therapy  
Oral or i.v. diuretics are allowed and may be adjusted during the treatment period.  
(Treatment with oral diuretics is allowed if o ngoing at a stable dose  for at least 48 h prior 
to the Baseline RHC. ) 
5.2.4 Prohibited concomitant therapy  
• PAH-specific therapy (ERAs, i.v., s.c., inhaled or oral prostanoids, PDE5 inhibitors, 
guanylate cyclase stimulators).  
• iNO. 
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir,saquinavir, boceprevir, telaprevir, iopi[INVESTIGATOR_054], fosamprenavir, darunavir, tipranavir, atazanavir, nelfinavir, amprenavir, and idinavir) and strong inducers of CYP3A4 (e.g., carbamazepi[INVESTIGATOR_050], rifampi[INVESTIGATOR_2513], rifabutin, phenytoin and St. John’ s Wort). 
• Any investigational drug. 
Initiation of one of these prohibited medications will lead to premature discontinuation of 
study treatment . 
Macitentan / ACT-[ADDRESS_327888]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 57/103 Confidential  Doc No D-17.154 
 
 5.3 Allowed LVAD flow rate  
The LVAD pump speed/flow rate may be adjusted during the treatment period , and 
during the Baseline RHC.  
(The LVAD pump speed/flow rate must be stable  for at least 48 h prior to Baseline 
RHC.) 
[ADDRESS_327889] d ose of study treatment . 
6.1 Efficacy endpoints  
6.1.1 Primary efficacy endpoint(s)  
The primary efficacy endpoint is PVR ratio of Week 12 to Baseline. PVR is obtained by 
[CONTACT_269386]. 6.1.2 Secondary efficacy endpoints  
• Change from Baseline to Week 12 in mean ri ght atrial pressure (mRAP), mPAP, 
PAWP, CI, total pulmonary resistance (TPR), and mixed venous oxygen saturation (SVO
2), all measured at rest.  
• Change from Baseline to Week 12 in NT- proBNP. 
• Change from Baseline to Week 12 in WHO FC. 
6.1.3 Exploratory efficacy end points 
• Change from Baseline to Week 12 in echocardiographic variables that include: − 2D global RV longitudinal strain (global RVLS) 
− RV sphericity index (RVSI) 
− RV end systolic area  
− RV end diastolic area  
− Tricuspid annular plane systolic excursion (TAPSE)  
− Tricuspid peak annular velocity s’ (S’) 
− RV fractional area change (RVFAC)  
− Tricuspid peak diastolic annular velocities e ’, a’ (E’, A’) 
• Time to first occurrence of clinical events, from enrollment to Week 12. These clinical events include:  
− Hospi[INVESTIGATOR_14831]  
− Re-initiation of i.v.  diuretics ≥ 48 h duration 
− Re-initiation of i.v. inotropes ≥ 48 h duration  
Macitentan / ACT-[ADDRESS_327890]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 58/103 Confidential  Doc No D-17.154 
 
 − Initiation of PDE5 inhibitors 
− Need for RVAD / total artificial heart (TAH)  
− Need for renal replacement therapy (RRT)  
− Death 
• Days in the hospi[INVESTIGATOR_269364]. 
• Change in GFR from Baseline to Week 12. 
6.2 Safety endpoints  
• Treatment -emergent AEs up to 30 days after study treatment discontinuation. 
• AEs leading to premature discontinuation of study treatment. 
• Death up to 30 days after study treatment discontinuation. 
• Treatment -emergent SAEs up to 30 days after study treatment discontinuation. 
• Change from Baseline to EOT in vital signs. 
• Occurrence of liver function test (ALT and/or AST) abnormality (≥ 3 × ULN; ≥ 3 and  
< 5 × ULN; ≥ 5 and < 8 × ULN; ≥ 8 × ULN) up to EOT. 
• Occurrence of ALT and/or AST abnormality ≥ 3 × ULN associated with bilirubin ≥ 2 × ULN up to EOT.  
• Proportion of patients  with treatment -emergent hemoglobin abnormality (< 10.0 g/dL, 
and < 8.0 g/dL) as compared to Baseline up to EOT. 
• Treatment -emergent marked laboratory abnormalities up to EOT. 
Marked laboratory abnormalities are defined in the central laboratory manual.  
6.3 Biomarker endpoints  
Change in NT -proBNP will be assessed from Baseline to Week 12 (EOT) as part of the 
secondary efficacy endpoints analysis [see Section 6.1.2]. Additional circulating 
biomarkers may be analyzed in  an exploratory format (post -hoc) based on available 
scientific evidence. No genetic testing will be performed.  
7 STUDY ASSESSMENTS 
All study assessments are performed by a qualified study staff member: medical, nursing, or specialist technical staff, and are recorded in the eCRF, unless otherwise specified. Study assessments performed during Unscheduled V isits will also be recorded in the 
eCRF. When applicable, the assessments should be performed in the following order: • Blood sampling 
• Physical examination  
Macitentan / ACT-[ADDRESS_327891]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 59/103 Confidential  Doc No D-17.154 
 
 • WHO FC  
• RHC at rest  
• Echo (i.e., 3D, 2D, M-mode and Doppler echocardiography)  
If the PI [INVESTIGATOR_180454]/assessment for a subject, e.g., RHC, blood sampling etc., to an external facility, he/she should inform Actelion of to whom these tasks are delegated. The set -up and oversight will be agreed upon with Actelion. The 
supervision of any external facilities remains under the responsibility of the PI. Calibration certificates for the following devices used to perform study assessments must be available prior to the Randomization of the first subject:  
• Temperature measurement devices for study medication storage area and freezer  
• RHC equipment  
• Scale for measuring body weight 7.1 Screening/Baseline assessments  
Date of informed consent, Baseline demograph ics (sex, age, race, ethnicity, body weight, 
height) as well as a reason for why a woman is not considered to be of child -bearing 
potential (if applicable) are to be recorded in the eCRF at Visit 1  / Screening only after 
Informed Consent has been signed. Complete, clinically relevant medical history (previous and ongoing at Randomization) 
as described in Section 4.6 and disease characteristics, vital signs, body mass index 
(BMI), and previous/ongoing medications [see Section  5.2.2] are to be documented in the 
eCRF at Visit 1  / Screening. Historical data of pre -LVAD RHC and non -Baseline 
post-LVAD RHC may be entered into the eCRF.   
A physical examination of the subject should be performed at Visit 1  / Screening and 
Visit 2 / Randomization. Data are not collected in the eCRF though abnormal findings are to be recorded as AEs.  
Reason for Screen ing failure, if applicable,  must be recorded in the eCRF.  
Serum laboratory and pregnancy testing should be performed at Visit 1 / Screening and repeated at Visit 2  / Randomization, whereas blood sampling for Baseline NT -proBNP 
should only be performed at Visit 2 / Randomization. At Visit 2  / Randomization, WHO FC, vital signs, and body weight is to be assessed and 
ongoing medications are to be collected in the eCRF. Study medication is dispensed at this visit.  
Macitentan / ACT-[ADDRESS_327892]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 60/[ADDRESS_327893] clinical or hemodynamic evidence of PH (e.g., PVR > 3  WU) on 
pre-LVAD RHC or immediate post -LVAD hemodynamics . Subjects without clinical or 
hemodynamic evidence of PH should not be screened for the study.  The patient must be stable for 48 h prior to the Baseline RHC. Stabilization is defined as:  
• No LVAD pump speed/flow rate changes, and  
• Stable dose of oral diuretics, and  
• No i.v. inotropes or vasopressors, and   
• Patient able to ambulate.   
 
Baseline RHC is defined as the last hemodynamic measurements after LVAD implantation and prior to first dose of study treatment.  Hemodynamic evidence of PH on 
Baseline RHC  is one of the inclusion criteria of SOPRANO. PH is defined as:  mPAP 
≥ 25 mmHg , PAWP ≤ 18 mmHg  and PVR > [ADDRESS_327894] dose of study treatment (which must occur within [ADDRESS_327895] -surgical implantation of LVAD, see Section 3). Randomization (Visit 2) 
must be within 14 days of Baseline RH C. Patients are excluded if they were treated  with 
ERAs, PDE5 inhibitors, i.v., s.c., or oral prostanoids, or guanylate cyclase stimulators within 7 days prior to Baseline RHC or study treatment initiation. Patients are excluded if 
they were treated  with inhaled prostanoids (e.g., iloprost, epoprostenol), nitric oxide or 
i.v. inotropes or vasopressors within 24 h prior to Baseline RHC or study treatment  
initiation. LVAD pump speed/flow rate may be adjusted during the treatment period and 
during the Baseline RHC.  
An RHC is repeated at Week 12, or within [ADDRESS_327896] and Data Worksheet (as 
Macitentan / ACT-[ADDRESS_327897]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 61/103 Confidential  Doc No D-17.154 
 
 provided by [CONTACT_180494]) must be completed and signed by [CONTACT_978] , and filed at site in the 
subject’s file. 
The following variables are to be measured and collected in the eCRF: pulse rate, PAWP, mRAP, systolic/diastolic/mean PAP, CO, and SVO2. Non-invasive mean, SBP and DBP 
if available, are collected and entered into the eCRF. PVR will be calculated locall y and 
entered into the eCRF. CO measurements, and PVR calculations, during both Baseline and Week [ADDRESS_327898] be based on thermodilution method- calculated PVR.  
The following hemodynamic variables will be calculated by [CONTACT_269408] [see Section 11.2 and the SOPRANO Right Heart Catheterization Instructions 
for formulae]: PVR, TPR, and CI. 7.2.2 WHO functional class  
WHO FC is evaluated at Baseline/Randomization and EOT.  
7.2.3 Serum NT -proBNP 
A blood sample will be drawn at Randomization (Visit 2) and EOT (Visit 5) for the analysis of serum NT -proBNP. 
Serum NT -proBNP samples will be stored frozen at −20  °C (−4 °F) ± 2 °C (± 3.6 °F). A 
temperatur e log must be maintained and temperature control should occur at least on a 
weekly basis. NT -proBNP samples will be processed through the central laboratory and 
the results will be sent electronically to Actelion on an ongoing basis. Further details regarding blood sampling procedures, collection and shipment of biomarker samples are 
described in the central laboratory manual.  
7.2.4 Echocardiography 
Echo (i.e., 3D, 2D, M -mode and Doppler echocardiography) will be performed according 
to the guidelines detailed in the Actelion Echo image acquisition protocol  on 
Visit 2 / Randomization, which will represent the Baseline measurements and be repeated at the Week [ADDRESS_327899] occur on the day of Randomization. Complete 
results will be blinded to the patient identity and to the date of image acquisition. The following variables will be centrally assessed according to a dedicated charter, and the results sent to Actelion:  
• 2D RVLS  
• RVSI 
• RV end systolic area  
• RV end diastolic area  
Macitentan / ACT-[ADDRESS_327900]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 62/103 Confidential  Doc No D-17.154 
 
 • TAPSE  
• S’ 
• RVFAC 
• E’, A’ 
7.2.[ADDRESS_327901] occurrence of clinical events, from enrollment to Week 12 will be recorded. These clinical events include:  
• Hospi[INVESTIGATOR_14831]  
• Re-initiation of i.v. diuretics ≥ 48 h duration.  
• Re-initiation of i.v. inotropes ≥ 48 h duration.  
• Initiation of PDE5 inhibitors 
• Need for RVAD/TAH  
• Need for RRT  
• Death 
Hospi[INVESTIGATOR_269369], as an exploratory endpoint, will be adjudicated by [CONTACT_269409].  
7.2.6 Duration of heart failure hospi[INVESTIGATOR_269370], excluding rehabilitation stay. A hospi[INVESTIGATOR_269371] a hospi[INVESTIGATOR_269372]. Hospi[INVESTIGATOR_269369], as an exploratory endpoint, will be adjudicated by [CONTACT_269409].  
7.2.7 Glomerular filtration rate  
Change in GFR from Baseline to Week 12 will be recorded. GFR will be estimated on the basis of serum creatinine levels. The formula can be found in the central laboratory 
manual. 7.3 Safety assessments  
The definitions, reporting and follow -up of AEs, SAEs, and pregnancies  are described in 
Section 10.  
7.3.1 Vital signs  
Vital signs (BP, pulse rate) will be measured via Doppler at Screening (Visit 1), Randomization (Visit 2), and EOT (Visit 5), and collected in the eCRF. BP (mean, systolic and diastolic, if available) and pulse rate will be measured in a supi[INVESTIGATOR_269373] / ACT-[ADDRESS_327902]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 63/[ADDRESS_327903]. 7.3.2 Weight and height  
Height will be measured at Visit 1  / Screening. Body weight will be measured at 
Visit 1 / Screening, Randomization, a nd EOT. 
7.3.3 Physical examination  
Physical examination (i.e., inspection, percussion, palpation and auscultation) is to be performed during the  Screening period (Visit 1) and EOT. The data are not collected in 
the eCRF, but clinically relevant findings that are  present at the signing of Informed 
Consent must be recorded on the Medical History eCRF page, while physical 
examination findings made after the signing of Informed Consent and which meet the 
definition of an AE [Section 10.1.1]  must be recorded by [CONTACT_269410].  
7.3.4 Laboratory assessments 
[IP_ADDRESS] Type of laboratory 
A central laboratory (see central laboratory manual for contact [CONTACT_8972]) will be used for all protocol-mandated laboratory tests, i ncluding re -tests due to laboratory abnormalities and 
laboratory tests performed at Unscheduled V isits. Central laboratory data will be 
automatically transferred from the central laboratory database to Actelion ’s clinical 
database.  
• For the follow -up of abnormal values such as ALT/AST and/or hemoglobin 
[see Section  5.1.11] central la boratory specimens must be obtained in parallel with 
local laboratories for re-test and prior to reintroduction of study treatment.  
Local laboratory results will be collected in the following situations:  • In case of missing central laboratory values, any local laboratory values noted as 
significant are to be recorded in the eCRF, especially  local laboratory results related 
to the diagnostic work -up (i.e., detection, confirmation and/or monitoring) of 
ALT/AST elevations and hemoglobin decreases. In the event that several local 
laboratory samples are taken on the same day or if the sample was tested several times, the  significance of the  ‘worst’ value (e.g., highest value for ALT/AST, lowest 
value for hemoglobin) should be reported in the eCRF. 
• In exceptional cases (e.g., subject is hospi[INVESTIGATOR_42868] a different hospi[INVESTIGATOR_269374] a medical emergency) where a local laboratory is used for the collection 
Macitentan / ACT-[ADDRESS_327904]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 64/103 Confidential  Doc No D-17.154 
 
 and analysis of blood samples, the results noted as significant will be entered into the 
clinical database via dedicated eCRF pages. For local laboratories, the investigator/delegate will provide Actelion with the name, professional degree a nd 
curriculum vitae (CV) of the laboratory director, a copy of the laboratory ’s 
certification, and the normal ranges for each laboratory test that is evaluated in the study. These laboratory references must be updated whenever necessary. 
• At the time of Screening, local laboratory results may be used for checking subject 
eligibility (since central laboratory results would not be available immediately). Central lab oratory results should be collected once eligibility is confirmed. 
Laboratory variables required  at Visit 2 are repeated at the central laboratory to be 
used as the Baseline values for safety laboratory endpoints specified in the protocol. 
Laboratory certification / reference ranges / laboratory director’ s CV will be collected 
by [CONTACT_269411]/or safety databases.  
If a central laboratory sample is lost, has deteriorated or cannot be analyzed for whatever reason, the investigator will collect an additional sample as soon as possible for repeat analysis, unless a local laboratory sample was collected within the same time-window and these test results are available.  
Central laboratory reports will be sent to the investigator. In case of specific (pre -defined) 
laboratory abnorma lities, the central laboratory will alert Actelion and the concerned site. 
Alert flags that will trigger such notifications are displayed in the central laboratory manual. All laboratory reports must be signed and dated by [CONTACT_269412] 
3 working days of receipt and filed with the source documentation. The investigator/delegate must indicate on the laboratory report whether abnormal values are considered clinically relevant or not. Clinically relevant laboratory findings that are known at the time of signature [CONTACT_269429] C onsent must be recorded on the medical 
history page of the eCRF. Any clinically relevant laboratory abnormalities detected after signature [CONTACT_269429] C onsent must be reported as an AE or SAE as appropriate 
[see Secti on 10], and must be followed until the value returns to within the normal range 
or is stable, or until the change is no longer clinically relevant. Further laboratory analyses should be performed as indicated an d according to the judgment of the 
investigator.  
Details about the collection, sampling, storage, shipment procedures, and reporting of results and abnormal findings can be found in the laboratory manual. The last lab oratory sample collected for the study will be analyzed prior to database lock. 
Laboratory samples will be destroyed within one year of database lock.  
Macitentan / ACT-[ADDRESS_327905]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 65/103 Confidential  Doc No D-17.154 
 
 [IP_ADDRESS] Laboratory tests  Hematology 
Hematology tests will be performed at every visit (Visits 1 to 6) and include:  
• Hemoglobin, hematocrit 
• Erythrocyte co unt 
• Leukocyte count with differential counts 
• Platelet count 
 Rules for study treatment  interruption in case of hemoglobin abnormalities are provided 
in Section 5.1.11. 
Clinical chemistry  
Clinical chemistry tests  will be performed at every visit (Visits 1 to 6) and include:  
• Aminotransferases (AST/ALT), alkaline phosphatase, total and direct bilirubin, lactate dehydrogenase (LDH)  
• Creatinine, blood urea nitrogen (BUN) 
• Uric acid 
• Glucose 
• Cholesterol, triglycerides  
• Sodium, potassium, chloride, calcium 
• Protein, albumin  
Rules for study treatment  interruption in case of liver function abnormalities are provided 
in Section 5.1.11. 
GFR 
GFR will be estimated on the basis of serum creatinine levels. The formula can be found in the central laboratory manual.  
Pregnancy test  
A serum pregnancy test for women of childbearing potential will be provided by [CONTACT_269413] [ADDRESS_327906] can be used; however, the subject must come to 
the site for a confirmatory serum pregnancy test to be performed by [CONTACT_2237].  
Macitentan / ACT-[ADDRESS_327907]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 66/[ADDRESS_327908] culating biomarkers such as: interleukin -6 (IL-6), 
tumor necrosis factor -α (TNF-α), high sensitivity C- reactive protein (hsCRP), ET -1, 
galectin-3, growth differentiation factor -15 (GDF -15), interleukin 1 receptor ST2, 
neutrophil gelatinase -associated lipocalin (NGAL), copeptin, high sensitivity cardiac 
troponin T (hs -cTnT), Cystatin-C and osteopontin, may be analyzed in an exploratory 
format (post- hoc) based on available scientific evidence.  
The last lab oratory sample collected for the study will be analyzed prior to database lock. 
Laboratory samples will be destroyed within one year of database lock.  
[ADDRESS_327909] be documented in the hospi[INVESTIGATOR_3853]. If the reason for non- eligibility was transient (e.g., abnormal laboratory test, insu fficient 
wash-out period of a prohibited medication, etc.), patients can be re- screened provided 
that documented authorization has been received from Actelion. All Screening 
assessments should then be repeated at the time of re- screening.  
 
8.1 Screening period  
8.1.1 Screening (Visit 1)  
All Screening assessments must be performed within the 90-day Screening period, 
beginning with LVAD implantation and prior to Randomization. Historical data of 
pre-LVAD RHC and non-Baseline post -LVAD RHC may be entered into the eCRF.   
It is the responsibility of the investigator to obtain written Informed C onsent from each 
subject participating in this study after adequate face- to-face explanation of the 
objectives, methods, and potential hazards of the study. The subjects who agree to participate in the study must sign the ICF prior to any study -related assessment or 
procedure.  The date of Informed Consent should be recorded as the date of the Screening visit in 
IxRS. 
Screening and Randomization can occur on the same day, provided that  all procedures of 
Visit 1 are completed before the procedures of Visit 2 are initiated.  
Macitentan / ACT-[ADDRESS_327910]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 67/103 Confidential  Doc No D-17.154 
 
 Visit 1 includes:  
• ICF signature. 
• Obtain subject number from IxRS. 
• Recording of demographics, B aseline characteristics, and medical history . 
• Recording of previous and concomitant medications. 
• Physical examination. 
• Measurement of vital signs, height and body weight. 
• Complete laboratory tests, including pregnancy test for women of childbearing potential. 
• Recording of methods of contraception (for females of childbearing potential only) and initiation of protocol -compliant contraception if applicable. The reason why a 
female is not considered to be of childbearing potential will also be collected in the eCRF. 
• RHC (unless the procedure was already performed and would be within 90 days of 
Randomization, and per the requirements described in Section 7.2.1).  
• Recording of AEs and SAEs.  
The investigator will check all the inclusion/exclusion criteria and decide on the subject ’s 
eligibility for the study. It must be verifiable in the source documents that the subject met each of the inclusion criteria and none of the exclusion criteria. If the subject is a Screen 
failure and not randomized, the reason for S creen failure is to be document ed in the IxRS 
system and in the eCRF.  8.2 Double-blind study treatment period  
8.2.1 Randomization (Visit 2) 
Visit 2 corresponds to the start of the treatment period (Day 1 of the study) for subjects that are eligible after all Screening assessments have been performed. It must be within 
90 days after LVAD i mplantation  and within 14 days of Ba seline RHC.  
Visit 2 includes:  
• Recording of changes in concomitant medications. 
• Measurement of vital signs and body weight. 
Macitentan / ACT-[ADDRESS_327911]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 68/103 Confidential  Doc No D-17.154 
 
 • Complete laboratory tests, including serum pregnancy test for women of childbearing potential. 
• Assessment of methods of contraception (for females of childbearing potential only). 
• Blood sample for serum NT-proBNP.  
• Blood sample for additional circulating biomarkers such as: IL-6, TNF-α, hsCRP, 
ET-1, galectin- 3, GDF-15, interleukin 1 receptor ST2, NGAL, copeptin, hs -cTnT, 
Cystatin-C and osteopontin, will be collected and may be analyzed in an exploratory 
format (post- hoc) based on available scientific evidence.  
• WHO FC .  
• Echo (i.e., 3D, 2D, M -mode and Doppler echocardiography) will be performed. 
Those include: TAPSE, S’ , RVFAC, E ’, A’, global RVLS, RV area and RVSI. 
Additionally, right and left ventricular echo variables may be analyzed in an 
exploratory format (post -hoc) based on available scientific evidence.  Baseline ECHO 
must occur on the day of Randomization. 
• Recording of AEs/SAEs. 
After completion of all Screening and Randomization assessments and confirmation of eligibility (i.e., verification of all entry criteria) by [CONTACT_093]:  
• Randomization via IxRS to obtain Randomization and study treatment bottle number. 
• Dispensing of 1 bottle of study treatment [see Section  [IP_ADDRESS]]. 
8.2.2 Week 4 (Visit 3) 
Visit 3 is scheduled 4 weeks (± 7 days) after Randomization. Visit 3 includes: • Recording of changes in concomitant medications.  
• Complete laboratory tests, including serum pregnancy test for women of childbearing potential. 
• Assessment of methods of contraception (for females of childbearing potential only). 
• Recording of AEs and SAEs . 
• Dispensing of 1 bottle of study treatment [see Section  [IP_ADDRESS]]. 
• Study medication return; subjects are asked to return all used, partially used, and unused study treatment bottles [see Section  [IP_ADDRESS]]. 
Macitentan / ACT-[ADDRESS_327912]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 69/103 Confidential  Doc No D-17.154 
 
 8.2.3 Week 8 (Visit 4) 
Visit 4 is scheduled 8 weeks (± 7 days) after Randomization. Visit 4 includes:  
• Recording of cha nges in concomitant medications. 
• Complete laboratory tests, including serum pregnancy test for women of childbearing potential. 
• Assessment of methods of contraception (for females of childbearing potential only). 
• Recording of AEs and SAEs. 
• Dispensing of 1 bottle of study treatment [see Section  [IP_ADDRESS]]. 
• Study medication return; subjects are asked to return all used, partially used, and unused study treatment bottles [see Section  [IP_ADDRESS]]. 
8.2.4 End-of-Treatment (Visit 5)  
EOT is scheduled 12 weeks (± 7 days) after Randomization, or earlier in case of premature discontinuation of study treatment.  EOT includes: • Recording of changes in concomitant medications. 
• Physical examination. 
• Measurement of vital signs and body weight. 
• Complete laboratory tests, including serum pregnancy test for women of childbearing potential. 
• Assessment of methods of contraception (for females of childbearing potential only). 
• RHC. 
• Blood sample for serum NT-proBNP.  
• Blood sample for additional circulating biomarkers such as: IL -6, TNF-α, hsCRP, 
ET-1, galectin- 3, GDF-15, interleukin 1 receptor ST2, NGAL, copeptin, hs -cTnT, 
Cystatin-C and osteopontin, will be collected and may be analyzed in an exploratory 
format (post- hoc) based on available scientific evidence.  
• WHO FC .  
Macitentan / ACT-[ADDRESS_327913]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 70/103 Confidential  Doc No D-17.154 
 
 • Echo (i.e., 3D, 2D, M -mode and Doppler echocardiography) will be performed. 
Those include: TAPSE, S’ , RVFAC, E ’, A’, global RVLS, RV area and RVSI. 
Additionally right and left ventricular echo variables may be analyzed in an 
exploratory format (post -hoc) based on available scientifi c evidence. 
• Study medication return; subjects are asked to return all used, partially used, and unused study treatment bottles [see Section  [IP_ADDRESS]]. 
• Recording of AEs and SAEs. 
8.2.5 End-of-Study (Visit 6)  
Subjects wh o complete the study as planned, i.e., full 12- week study period and those 
who prematurely discontinue study treatment  will enter a [ADDRESS_327914] 30 days (+ 7 days) after the permanent discontinuation of study treatment (last dose of study drug). EOS includes: • Recording of cha nges in concomitant medications. 
• Complete laboratory tests, including serum pregnancy test for women of childbearing potential. 
• Assessment of methods of contraception (for females of childbearing potential only). 
• Recording of A Es and SAEs.  
8.2.6 Unscheduled Visits (U1, U2, etc)  
Unscheduled V isits may be performed at any time during the study. Depending on the 
reason for the Unscheduled V isit (e.g., loss of efficacy, AE), appropriate ass essments 
[as specified in  Table 1] may be performed based on the judgment of the investigator and 
must be recorded in the eCRF. After an Unscheduled V isit, the regular scheduled study 
visits must continue according to the planned visit and assessment schedule.  [ADDRESS_327915]-STUDY TREATMENT/MEDI CAL 
CARE 
9.[ADDRESS_327916], the study is considered completed once EOT has been performed and the 30-day safety follow- up is complete (EOS ). 
The study is considered complete when all subjects have completed as detailed above. The planned study duration is approximately [ADDRESS_327917] visit.  
Macitentan / ACT-[ADDRESS_327918]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 71/[ADDRESS_327919] fro m the study (without regard to the subject ’s consent) if, on balance, they 
believe that continued participation in the study would be contrary to the best interests of the subject. Withdrawal from the study may also result from a decision by [CONTACT_180505], including premature termination or suspension of the study [see Section  9.3]. 
Subjects are considered as lost to follow -up if all reasonable attempts by [CONTACT_269414]. The site must take preventive measures to avoid 
a subject being lost to follow -up (e.g., document different ways of contact [CONTACT_42923], home address, e -mail address, person to be contact[CONTACT_180507]). If  the subject cannot be reached, the site must make a 
reasonable effort to contact [CONTACT_423], document all attempts and enter the loss of follow-up information into the eCRF. The following methods must be used: at least three 
telephone calls must be placed to the last available telephone number, and one registered letter must be sent by [CONTACT_215253]. Additional methods may be acceptable if they are compliant with local rules/regulations (e.g., site staff visit to the subject’s home), respecting the subject ’s right to privacy. If the subject is still 
unreachable after all contact [CONTACT_42927], he/she will be considered to be lost to follow-up.  If premature withdrawal occurs for any reason, the reason for premature withdra wal from 
the study, along with who made the decision (subject, investigator or Actelion) must be recorded in the eCRF.  
If, for whatever reason (except death or loss -to-follow-up), a subject was withdrawn from 
the study, the investigator should make efforts  to conduct a last visit/contact [CONTACT_269415] -being of the subject, collect unused study drug and discuss follow -up 
medical care. The investigator must provide follow -up medical care for all subjects who 
are prematurely withdrawn from the study, or must refer them for appropriate ongoing 
care, as described in Section  9.4. 
9.3 Premature termination or suspension of the study 
Actelion reserves the right to terminate the study at any time globally or lo cally. 
Investigators can terminate the participation of their site in the study at any time.  
If a study is prematurely suspended or terminated, Actelion will promptly inform the investigators, the IRBs/IECs, and Health Authorities, as appropriate, and provide the reasons for the suspension or termination. 
Macitentan / ACT-[ADDRESS_327920]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 72/[ADDRESS_327921] promptly inform all enrolled subjects, and ensure their appropriate treatment and follow -up, as described in Section  9.2. Actelion may inform 
the investigator of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the subjects’ interests. In addition, if the investigator suspends or terminates a study without prior agreement from Actelion, the investigator must promptly inform Actelion and the IRB/IEC, and provide both with a detailed written explanation of the termination or suspension. If the IRB/IEC suspends or terminates its approval/favorable opi[INVESTIGATOR_1101] a study, the investigator must promptly notify Actelion and provide a detailed written explanation of the termination or suspension. Any suspension or premature termination of the study must be discussed with the IDMC and Steering Committee . 9.4 Medical care of subjects after study completion/withdrawal from study 
After the subject ’s study completion or premature withdrawal from the study, whichever 
applies, the investigator/delegate will explain to subjects what treatment(s)/medical care is necessary and available according to local regulations.  
After premature study withdrawal, the investigator must remind the subject that he/she must not use any other investigational treatment in the [ADDRESS_327922] during the course of the study, whether or not considered by [CONTACT_155681]. AEs include: • Exacerbation of a pre- existing disease.  
Macitentan / ACT-[ADDRESS_327923]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 73/103 Confidential  Doc No D-17.154 
 
 • Increase in frequency or intensity of a pre -existing epi[INVESTIGATOR_42861]. 
• Disease or medical condition detected or diagnosed during the course of the study 
even though it may have been present prior to the start of the study. 
• Continuous persistent disease or symptoms present at study start that worsen following the start of the study (i.e., signing of informed consent). 
• Abnormal assessments, e.g., change on physical examination, ECG findings, if they represent a clinically significant finding that was not present at study start or worsened during the course of the study. 
• Laboratory test abnormalities if they represent a clinically significant finding, symptomatic or not, which was not present at study start or worsened during the course of the study or led to dose reduction, interruption or permanent discontinuation of study treatment. 
A treatment -emergent AE is any AE temporally associated with the use of study 
treatment (from study treatment  initiation until 30 days after study treatment  
discontinuation), whether or not considered by [CONTACT_155681]. Overdose, misuse,  and abuse of the study treatment  should be reported as an AE and, in 
addition, study treatment errors must be documented in the study drug log of the eCRF. 10.1.2 Intensity of adverse events 
The intensity of clinical AEs is graded on a three -point scale – mild, moderate, severe – 
and is reported on specific AE pages of the eCRF.  
If the intensity of an AE worsens during study treatment  administration, only the worst 
intensity should be reported on the AE page. If the AE lessens in intensity, no change in the severity is required.  
If the intensity of an AE with an onset date between Informed C onsent signature [CONTACT_269430] , a new AE page must be completed. The onset date of this new AE 
corresponds to the date of worsening in intensity. The three categories of intensity are defined as follows:   Mild 
The event may be noticeable to the subject. It does not influence daily activities, and usually does not require intervention. 
Macitentan / ACT-[ADDRESS_327924]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 74/103 Confidential  Doc No D-17.154 
 
  Moderate  
The event may make the subject uncomfortable. Performance of daily activities may be influenced, and intervention may be needed. 
 Severe 
The event may cause noticeable discomfort, and usually interferes with daily activities. The subject may not be able to continue in the study, and treatment or intervention is usually needed.  
A mild, moderate, or severe AE may or may not be serious [see Section  10.3.1]. These 
terms are used to describe the inten sity of a specific event. Medical judgment should be 
used on a case-by- case basis.  
Seriousness, rather than severity assessment, determines the regulatory reporting obligations. 10.1.[ADDRESS_327925] ’s previous 
treatment during a washout period leading to exacerbation of underlying disease. 10.1.[ADDRESS_327926] be followed up until they are no longer considered clinically relevant. 
Macitentan / ACT-[ADDRESS_327927]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 75/103 Confidential  Doc No D-17.154 
 
 10.2 Serious adverse events  
10.2.1 Definitions of serious adverse events  
[IP_ADDRESS] Serious adverse events  
An SAE is defined by [CONTACT_269416]:  
• Fatal. 
• Life-threatening: refers to an event in which the subject was at risk of death at the 
time of the event. It does not refer to an event that hypothetically might have caused death had it been more severe.  
• Requiring inpatient hospi[INVESTIGATOR_059], or prolongation of existing hospi[INVESTIGATOR_059]. 
• Resulting in persistent or significant disability or incapacity.  
• Congenital anomaly or birth defect. 
• Medically significant: refers to important medical events that may not immediately result in death, be life -threatening, or require hospi[INVESTIGATOR_42862], based upon appropriate medical judgment, they may jeopardize the subject, and may require medical or surgical intervention to prevent one of the outcomes listed in the de finitions above. 
The following reasons for hospi[INVESTIGATOR_180457]: • Hospi[INVESTIGATOR_180458], or social and/or convenience reasons.  
• Hospi[INVESTIGATOR_5912] -planned (i.e., planned prior to signing informed conse nt) 
surgery or standard monitoring of a pre -existing disease or medical condition that did 
not worsen, e.g., hospi[INVESTIGATOR_42865] a subject with stable angina pectoris. 
However, complications that occur during hospi[INVESTIGATOR_269375] (for example, 
if a complication prolongs hospi[INVESTIGATOR_059]).  
10.2.[ADDRESS_327928] be reported on AE pages in the eCR F of study 
AC-055-205, and on an SAE form, regardless of the investigator -attributed causal 
relationship with study treatment  or study-mandated procedures.  
Macitentan / ACT-[ADDRESS_327929]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 76/[ADDRESS_327930] be reported to the Actelion 
Drug Safety department within 24 h of the investigator ’s knowledge of the event, only if 
considered by [CONTACT_42930]. 10.2.[ADDRESS_327931] be reported by [CONTACT_269417] 24 h of the investigator’s first knowledge of the event. All SAEs must be recorded on an SAE form, irrespective of the study treatment  received 
by [CONTACT_423], and whether or not this event is considered by [CONTACT_41708]. 
The SAE forms must be faxed to the Actelion Drug Safety department (contact [CONTACT_180514]). The investigator must complete the SAE form in English, 
and must assess the causal relationship of the event to study treatment. Follow-up information about a previously reported SAE must also be reported within 
[ADDRESS_327932] is hospi[INVESTIGATOR_42868] a hospi[INVESTIGATOR_42869], it is the investigator ’s 
responsibility to contact [CONTACT_42933][INVESTIGATOR_269376]. The reference safety document to assess expectedness of a suspect serious adverse reaction and reported by [CONTACT_180515], IRBs/IECs, and investigators is the reference safety information section of the Investigator’ s 
Brochure [ Macitentan  IB]. 
The following events that are expected to occur in patients with P AH/PH will be 
considered as ‘disease-related’ and ‘expected’ for regulatory reporting purposes in this 
population: signs and symptoms of PAH/PH worsening/exacerbation/progression, including fatal outcome, and, in particular, abdominal pain, anorexia, chest  pain, 
cyanosis, diaphoresis, dizziness, pre -syncope, dyspnea, orthopnea, fatigue, hemoptysis, 
HF, hypoxia, palpi[INVESTIGATOR_814], syncope, collapse, systemic arterial hypotension, and tachycardia. These SAEs must also be reported on AE pages in the eCRF and on an SAE 
form by [CONTACT_269418] 24 h of the investigator’s first knowledge of the event.  
Macitentan / ACT-[ADDRESS_327933]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 77/[ADDRESS_327934] be reported within 24 h of the investigator ’s knowledge of the 
event. Pregnancies must be reported on the Actelion Pregnancy form, which is faxed to the Actelion drug safety department (see co ntact details provided on the Actelion Pregnancy 
form), and on an AE page in the eCRF. 10.3.[ADDRESS_327935] be reported on an SAE form as described in Section 10.3.1. 
10.4 Study safety monitoring  
Clinical study safety information (AEs, SAEs, laboratory values, ECGs, vital signs, and project-specific labs/examinations as required) is monitored and reviewed on a 
continuous basis by [CONTACT_208248] (in charge of ensuring subjects’ safety as 
well as data quality) by [CONTACT_180518]. In addition, an IDMC is monitoring data from the study and may recommend modification, discontinuation or completion of the study [see Section  3.3]. 
11 STATISTICAL METHODS  
All statistical analyses will be conducted by [CONTACT_269419]. A statistical analysis plan (SAP) will provide full details of the analyses, data displays, and algorithms to be used for data derivations.  
Macitentan / ACT-[ADDRESS_327936]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 78/103 Confidential  Doc No D-17.154 
 
 11.1 Analysis sets 
11.1.1 Screened Analysis Set  
This analysis set includes all patients who were screened and received a S creening 
number . 
11.1.2 Safety Set 
The Safety Set (SS) includes all patients who received at least one dose of study drug in the treatment period. 11.1.3 Full Analysis Set  
The Full Analysis Set (FAS) includes all patients randomized.  
11.1.[ADDRESS_327937] -Baseline 
PVR measurement.  
11.1.5 Per-Protocol Set 
The Per-Protocol Set (PPS) comprises all patients included in the modifie d FAS without 
major protocol deviations that affect the main analysis of the primary efficacy variable. The reasons for excluding patients from the PPS will be fully defined and documented in the SAP. 
11.1.[ADDRESS_327938] disposition will be described for the Screened Analysis Set. 
Macitentan / ACT-[ADDRESS_327939]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 79/103 Confidential  Doc No D-17.154 
 
 11.2 Variables 
11.2.1 Primary efficacy variable(s)  
The primary efficacy variable is PVR ratio of Week 12 to Baseline. PVR [WU] is 
calculated as (mPAP − PAWP) / CO.   
11.2.2 Secondary efficacy variables 
Secondary efficacy variables are changes from Baseline to Week 12 , for: 
• mRAP (mmHg)  
• mPAP (mmHg)  
• PAWP (mmHg)  
• CI (L/min/m2), calculated as CO / body surface area (BSA) where BSA 
(m2) = 0.007184 × weight0.425 (kg) × height0.725 (cm) 
• TPR (WU), calculated as mPAP / CO  
• SVO2 (%)  
• NT-proBNP (pmol/L) 
• WHO FC (I –IV). 
11.2.3 Exploratory efficacy variables 
• Echocardiographic variables including: − 2D global RVLS 
− RVSI 
− RV end systolic area  
− RV end diastolic area  
− TAPSE  
− S’ 
− RVFAC 
−  E’, A.’ 
• Clinical events including: 
− Hospi[INVESTIGATOR_14831]  
− Re-initiation of i.v. diuretics ≥ 48 h duration 
− Re-initiation of i.v. inotropes ≥ 48 h duration  
− Initiation of PDE5 inhibitors 
− Need for RVAD/TAH  
− Need for RRT  
− Death.  
• Days in the hospi[INVESTIGATOR_269377].  
Macitentan / ACT-[ADDRESS_327940]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 80/103 Confidential  Doc No D-17.154 
 
 • Change in GFR from Baseline to Week 12. 
11.2.4 Safety variables 
• Treatment -emergent AEs up to 30 days after study treatment discontinuation.  
• AEs leading to premature discontinuation of study treatment. 
• Death up to 30 days after study treatment discontinuation. 
• Treatment -emergent SAEs up to 30 days after study treatment discontinuation . 
• Change from Baseline to EOT in vital signs. 
• Proportion of patients with treatment- emergent ALT and/or AST abnormalities from 
Baseline up to EOT, classified as:  
− ≥ 3 × ULN; 
− ≥ 3 × ULN and < 5 × ULN; 
− ≥ 5 × ULN and < 8 × ULN; 
− ≥ 8 × ULN. 
• Proportion of patients with ALT and/or AST abnormality ≥ 3 × ULN in combination with total bilirubin ≥ 2 × ULN from Baseline up to EOT. 
• Proportion of patients with treatment- emergent h emoglobin abnormalities as 
compared to Baseline up to EOT, classified as:  
− < 8.0 g/dL 
− < 10.0 g/dL. 
• Treatment -emergent marked laboratory abnormalities up to EOT. 11.3 Description of statistical analyses  
11.3.1 Overall testing strategy  
The overall type I error is α  = 0.025 (one -sided). The type II error is set to 0.20 and the 
power to 80%. 11.3.2 Analysis of the primary efficacy variable(s)  
[IP_ADDRESS] Hypotheses and statistical model 
The null hypothesis is that the mean PVR ratio is the same in the macitentan and placebo groups. The altern ative hypothesis is that the mean PVR ratio is lower in the macitentan group as 
compared to the placebo group.  
Macitentan / ACT-[ADDRESS_327941]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 81/103 Confidential  Doc No D-17.154 
 
 [IP_ADDRESS] Handling of missing data 
If PVR cannot be calculated due to missing PAWP, but mPAP and CO are available for the same visit, one of the following will be applied: 1. If PAWP is missing both at Baseline and post -Baseline, the treatment group medians 
will be imputed (based on the FAS).  
2. If PAWP is missing either at Baseline or post- Baseline, the patient ’s available PAWP 
will be imputed.  
This imputation i s based on the clinical assumption that macitentan does not affect 
PAWP. 
Baseline: Patients without a Baseline PVR measurement will be excluded from the 
analyses.  
Post-Baseline: In patients with a post- Baseline PVR measurement obtained before 
Week 12, the last post- Baseline PVR measurement will be carried forward.  
If a patient has no post -Baseline PVR measurement, the ratio of Week 12 to Baseline 
PVR will be imputed using the treatment group median based on the FAS.  Other imputation methods for PVR values  will be considered (e.g., multiple imputations) 
as sensitivity analysis. Details will be specified in the SAP.  
[IP_ADDRESS] Main analysis 
The primary analysis will be performed on the FAS.  PVR will be summarized by [CONTACT_269420] (CVs). The ratio of Week 12 to Baseline PVR will be summarized similarly.  
The ratio of Week 12 to Baseline PVR will be log- transformed (base e) and analyzed 
using an analysis of covariance (A NCOVA) with a factor for treatment group and a 
covariate for Baseline log PVR (macitentan vs. placebo). The treatment group difference 
(on log scale) and its 95% CLs will be estimated based on the model. The geometric mean ratio (GMR; macitentan vs. placeb o) and its 95% confidence interval will be 
obtained by [CONTACT_151698]. The null hypothesis will be rejected if the entire 95% confidence interval is below one. The treatment effect will be expressed as (GMR−1) × 100%, where a negative value indicates a red uction of PVR in the macitentan group as compared to the placebo group. 
Macitentan / ACT-[ADDRESS_327942]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 82/[ADDRESS_327943] that ratios versus Baseline follow 
a normal distribution more closely after a log transformation. In addition, mean absolute changes from Baseline on log scale can be translated into (geometric) mean ratios by 
[CONTACT_151698]. [IP_ADDRESS] Supportive/sensitivity analyses  
The primary and selected secondary efficacy endpoints will be analyzed on the modified FAS as sensitivity analyses. Details of  supportive/sensitivity analyses will be specified in 
the SAP. 
[IP_ADDRESS] Subgroup analyses 
Additional subgroup analyses will be specified in the SAP. 11.3.3 Analysis of the secondary efficacy variable(s)  
Secondary efficacy analyses will be performed on the FAS at α =0.025 (one- sided) using 
95% CLs. No correction for multiple testing will be applied for these analyses. Changes from Baseline to Week 12 in pressure -volume variables (e.g., mRAP, mPAP, 
PAWP, CI TPR) and SVO2 will be summarized and analyzed as described in 
Section [IP_ADDRESS], but without the log-transformation. 
NT-proBNP will be summarized by [CONTACT_269421]. The ratio of Week 12 to Baseline NT-proBNP will be summarized similarly. The ratio versus Baseline in NT -proBNP will 
be log-transformed and analyzed using an ANCOVA with covariates for treatment group 
and Baseline log NT -proBNP. 
WHO FC will be summarized by [CONTACT_269422]. 
Changes from Baseline in WHO FC will be dichotomized as worsening (i.e., change >  0) 
versus no change or improvement (i.e., change ≤ 0). Worsening will be analyzed using a logistic regression model with covariates for treatment group and WHO FC.  
11.3.4 Analysis of the exploratory efficacy variable(s) 
Exploratory efficacy analyses will be performed on the FAS at α = 0.025 (one -sided) 
using 95% CLs. No correction for multiple testing will be applied for these analyses. Echocardiographic variables including TAPSE, S’ , RVFAC, E ’, A’, RVLS, RV area and 
RVSI will be summarized by [CONTACT_12268] (Baseline, Week 12/EOT) using 
descriptive statistics (n, mean, SD, median, Q1,  Q3, and range). The change from 
Baseline to Week 12/EOT in  these variables will be summarized similarly and analyzed 
using an ANCOVA with a factor for treatment and covariates Baseline log PVR and 
Macitentan / ACT-[ADDRESS_327944]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 83/103 Confidential  Doc No D-17.154 
 
 Baseline TAPSE, S’ , RVFAC, E ’, A’, RVLS, RV area and RVSI, respectively. The 
adjusted treatment effect and its 95% CI will be presented.  
Clinical events including: hospi[INVESTIGATOR_14831], re -initiation of i.v. diuretics ≥ 48 h, 
re-initiation of i.v. inotropes ≥ 48 h, need for RVAD/TAH, need for RRT and death will 
be summarized by [CONTACT_85839] -to-event treatment differences will be 
analyzed using the log- rank test. 
Duration of hospi[INVESTIGATOR_269378].  GFR will be summarized  by [CONTACT_12268] (Baseline, Week 12/EOT) using 
descriptive statistics (n, mean, SD, median, Q1, Q3, and range). The change from Baseline to Week 12/EOT in GFR will be summarized similarly. Change from Baseline in GFR will be analyzed using an A NCOVA with a factor for treatment and covariates 
Baseline log PVR and Baseline GFR. The adjusted treatment effect and its 95% confidence interval will be presented. 11.3.5 Analysis of the safety variable(s)  
The safety analyses described below will be performed on  the SS. All safety data will be 
listed, with flags for quantitative abnormalities.  
[IP_ADDRESS] Adverse events 
A treatment -emergent AE is any AE temporally associated with the use of a study 
treatment. The number and percentage of patients experiencing treatment -emergent AEs 
and SAEs at least once will be tabulated by [CONTACT_180526]: • MedDRA system organ class (SOC) and individual preferred term within each SOC, 
in descending order of incidence. 
• Frequency of patients with events coded with the same preferred term, in descending order of incidence.  
Furthermore, treatment- emergent AEs and SAEs will be tabulated as described above by 
[CONTACT_78621].  AEs leading to premature discontinuation of study treatment  and death will also be 
summarized as described above.  
Listings will be provided for all reported AEs, including SAEs. In addition, separate listings will be provided for SAEs, for AEs leading to premature discontinuation of study 
treatment, and for AEs leading to death. 
Macitentan / ACT-[ADDRESS_327945]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 84/103 Confidential  Doc No D-17.154 
 
 [IP_ADDRESS] Laboratory variables 
Descriptive summary statistics by [CONTACT_269423], in both hematology and blood chemistry laboratory tests. In order to minimize missing data and to allow for Unscheduled V isits, 
all recorded assessments up to EOT plus [ADDRESS_327946] fitting time -window for that assessment.  
The central laboratory manual outlines the definitions of marked abnorm alities and 
provides guidance for the standardization of numeric values obtained from different laboratories and/or using different normal ranges. Standard numeric laboratory variables are transformed to standard units. All laboratory data transferred are taken into account 
regardless of whether they correspond to scheduled (per -protocol) or unscheduled 
assessments.  
Marked laboratory abnormalities will be summarized for each laboratory variable by [CONTACT_180528]. Absolute values and changes from Baseline of laboratory values during the course of the study will be summarized using the usual location and scale summary statistics by [CONTACT_1570]. Laboratory variables are the following: • Hematology: hemoglobin, hematocrit, erythrocyte count, leukocyte count with differential counts, platelet count 
• Blood chemistry: AST, ALT, alkaline phosphatase, total and direct bilirubin, LDH, creatinine, BUN, uric acid, glucose, cholesterol, triglycerides, sodium, potassium, chloride, calcium, protein, albumin. 
The number and percentage of patients with liver function test abnormalities [classified as in Section  11.2.4] will be tabulated by [CONTACT_1570].  
The number and percentage of patie nts with hemoglobin abnormalities [classified as in 
Section 11.2.4]  will be tabulated by [CONTACT_1570]. 
[IP_ADDRESS] Vital signs and body weight 
Blood pressure (i.e., DBP and SBP), pulse rate, and body weight (in kg) will be 
summarized at each study visit using the usual location and scale summary statistics by [CONTACT_269424]. Patients for whom no post-Baseline value is available are excluded from the analysis of the chang es from 
Baseline in the SS.  
Macitentan / ACT-[ADDRESS_327947]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 85/[ADDRESS_327948] into the study. The composition and operation of the IDMC is described in the IDMC charter.  
11.5 Sample size 
11.5.1 Sample size justification  
There are no randomized clinical trial data in this patient population.  However, an 
integrated analysis of two bosent an studies, BENEFIT (AC -052-366) and EARLY 
(AC-052- 364), the hemodynamic substudy of SERAPHIN (AC -055-302), and the 
recently completed MERIT study (AC -055E201) of macitentan in patients with 
inoperable chronic thromboembolic pulmonary hypertension,  suggest that the treatment 
group difference on PVR is around − 0.28 on log scale (ranged from −0.45 to −0.17 with 
95% confidence interval:  −0.35, − 0.21) with the within group standard deviation (SD) 
around 0.40 on log scale (90% confidence interval:0.38, 0.42).  Based on the following assumptions: • Type I error of 2.5% (1 -sided); 
• 80% power; 
• Treatment assignment ratio 1:1 between placebo  and macitentan 10 mg; 
• Treatment group difference on PVR ratio of Week 12 to B aseline −0.28 (a GMR of 
0.76 macitentan/placebo);  
• Within group SD of 0.41; 
• A normal distribution for the log-transformed percent of B aseline PVR;  
70 evaluable patients will be needed for 80% power (35 patients per group)  to test the 
primary hypothesis of interest.  Accounting for 10% non- evaluable patients, 
approximately78 patients will need to be randomized.  11.5.2 Sample size sensitivity  
Table 2 gives more details about the integrated analysis of PVR. It also shows the ‘best’ 
and ‘worst’ case sample sizes based on the 95% CLs around the treatment effect for each 
study as well as for the integrated analysis. It appears that the proposed sample size of 
[ADDRESS_327949] to some deviations from the assumptions given above. 
Macitentan / ACT-[ADDRESS_327950]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 86/103 Confidential  Doc No D-17.154 
 
 Table 2 Treatment effects (differences on log -scale as well as % reduction 
versus placebo), variability in integrated analysis of four studies  
(AC-052- 366, AC -052-364, AC-055-302 and AC -055E201), and 
associated sample size for 80% power.   
Study Protocol Treatment 
Effect 95% CI 
of Effect SD 90% CI 
of SD Sample 
Size1 Best 
Case Worst 
Case 
EARLY AC-052-364 −0.26 −23% −0.41 −0.11 0.50 0.45 0.54 120 50 652 
BENEFIT AC-052-366 −0.25 −22% −0.35 −0.15 0.32 0.29 0.35 54 30 146 
SERAPHIN  AC-055-302 −0.45 −36% −0.58 −0.32 0.38 0.35 0.43 26 16 48 
MERIT AC-055E201 -0.17 −16% −0.29 −0.01 0.39 0.35 0.45 166 58 > 1000 
Overall  −0.28 −24% −0.35 −0.21 0.40 0.38 0.42 66 44 114 
1For 80% power and a two-sided alpha of 5% 
Best case: based on lower limit of 95% CI for effect 
Worst case: based on upper limit of 95% CI for  effect 
CI = confidenc e interval; PVR = pulmonary vascular resistance; SD = standard deviation.  
12 DATA HANDLING  
12.1 Data collection  
The investigator/delegate is responsible for ensuring the accuracy, completeness, and timeliness of the data reported. All source documents should be completed in a neat, legible manner to ensure accurate interpretation of the data. Data reported in the eCRF derived from source documents must be consistent with the source documents. eCRF data will be captured via electronic data capture. The investigator and site staff will be trained to enter and edit the data via a secure network, with secure access features (username, password, and identification – an electronic password system). A complete 
electronic audit trail will be maintained. The investigator/delegate will approve the data (i.e., confirm the accuracy of the data recorded) using an electronic signature. For each subject enrolled, regardless of study treatment initiation, an eCRF must be 
completed and signed by [CONTACT_093]/delegate. This also a pplies to those subjects 
who fail to complete the study. If a subject withdraws from the study, the reason must be noted on the eCRF. 
12.2 Maintenance of data confidentiality 
The investigator/delegate must ensure that data confidentiality is maintained. On eCRF s 
or other documents (e.g., documents attached to SAE reports) submitted to Actelion and any external service providers, subjects must be identified only by [CONTACT_6227], and never by 
[CONTACT_180555] / ACT-[ADDRESS_327951]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 87/103 Confidential  Doc No D-17.154 
 
 name [CONTACT_47623], hospi[INVESTIGATOR_42871], or any other identifier. The investigator/ delegate must 
keep a subject identification code list, at the site, showing the Screening/Randomization number, the subject ’s name, date of birth, and address or any other locally accepted 
identifiers. Documents identifying the subjects (e.g., signed ICFs)  must not be sent to 
Actelion, and must be kept in strict confidence by [CONTACT_093]/delegate. 12.[ADDRESS_327952] status at any time point during the course of the study.  While entering the data, the investigator/delegate will be instantly alerted to data que ries 
by [CONTACT_42940]. Additional data review will be performed by [CONTACT_180531]. If discrepant data are detected, a query specifying the problem and requesting clarification will be issued and visible to the investigator/delegate via the eCRF. All electronic queries visible in the system either require a data correction (when applicable) and a response from the investigator/delegate to clarify the queried data directly in the eCRF, or simply a data correction in the eCRF. The investigator/delegate must, on request, supply Actelion with any required background data from the study documentation or clinical records. This is particularly important when errors in data trans cription are suspected. In the case of 
Health Authority queries, it is also necessary to have access to the complete study records, provided that subject confidentiality is protected.  
This process will continue until database closure.  
Laboratory samples wi ll be processed through a central laboratory and the results will be 
sent electronically to Actelion.  
After the database has been declared complete and accurate, the database will be closed. Any changes to the database after that time may only be made as d escribed in the 
appropriate SOP. After database closure, the investigator will receive the eCRFs of the subjects of her/his site (including all data changes made) on electronic media or as a paper copy. 
Macitentan / ACT-[ADDRESS_327953]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 88/103 Confidential  Doc No D-17.154 
 
 13 PROCEDURES AND GOOD CLINICAL PRACTICE  
13.1 Ethics and Good  Clinical Practice  
Actelion and the investigators will ensure that the study is conducted in full compliance with ICH -GCP Guidelines, the principles of the “Declaration of Helsinki ”, and with the 
laws and regulations of the country in which the research is conducted. 
13.2 Independent Ethics Committee / Institutional Review Board  
The investigator will submit this protocol and any related document provided to the subject (such as the Subject Information Leaflet used to obtain informed consent) to an IRB/IEC. Appro val from the committee must be obtained before starting the study, and 
must be documented in a dated letter to the investigator, clearly identifying the study, the documents reviewed, and the date of approval. Modifications made to the protocol or subject information leaflet after receipt of the 
approval must also be submitted as amendments by [CONTACT_85213]/IEC in accordance with local procedures and regulations [see Section  13.6]. 
A list of members  participating in the IRB/IEC meetings must be provided, including the 
names, qualifications, and functions of these members. If that is not possible, the attempts made to obtain this information along with an explanation as to why it cannot be obtained or disclosed must be documented in the study documentation. If a study staff member 
was present during a meeting, it must be clear that this person did not vote. 
13.3 Informed Consent 
It is the responsibility of the investigator/delegate to obtain Informed C onsent according 
to ICH-GCP guidelines and local regulations from each individual participating in this 
study and/or legal representative. The investigator/delegate must explain to subjects that they are completely free to refuse to enter the study, or to withdraw from it at any time for any reason and without having to provide any justification. The ICF will be provided in English. Site staff authorized to participate to the consent process and/or to obtain consent from the subject and/or legal representative w ill be listed on an Actelion DoA form. A study 
physician must always be involved in the consent process. The subject and/or legal representative must sign, personally date, and time (if appropriate) the ICF before any study-related procedures (i.e., any procedures required by [CONTACT_760]) begin. The ICF must also be signed, personally dated, and timed (if the first 
Macitentan / ACT-[ADDRESS_327954]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 89/103 Confidential  Doc No D-17.154 
 
 study-mandated procedure was performed on the same day Informed C onsent was 
obtained) by [CONTACT_269425] f orm. 
A copy of the signed and dated ICF is given to the subject and/or legal representative; the original is filed in the site documentation. The Informed C onsent process must be fully 
documented in the subject ’s medical records. This must include the study reference, the 
subject number, the date and, if applicable, time when the subject was first introduced to the Actelion clinical study, ; the date and, if applicable, time of consent, who participated in the consent discussion, who consented the subject, and any additional person present during the consent process (e.g., subject family member), and a copy of the signed ICF given to the subject / legal representative.  
In the case that the site would like to recruit subjects who are considered as vulnerable (e.g., subject cannot read or write, does not speak or understand the ICF language), additional measures must be implemented in order to ensure subject’ s rights are respected 
and the consent obtained is legally valid. Actelion, the regulatory authorities ( if 
applicable), and the IRB/IEC must be informed prior to the recruitment. The consent process (e.g., involvement of an impartial witness) must be fully described, submitted to, and approved by [CONTACT_1201]/IEC, according to procedures and before subjects are r ecruited. 13.4 Compensation to subjects and investigators  
Actelion provides insurance in order to indemnify (with both legal and financial coverage) the investigator/site against claims arising from the study, except for claims that arise from malpractice and/o r negligence. 
The compensation of the subject in the event of study -related injuries will comply with 
applicable regulations.  
13.5 Protocol adherence/compliance  
The investigator must conduct the study in compliance with the approved version of the protocol and must not implement any deviation/change from the protocol, except when deviation is necessary to eliminate an immediate hazard to the subject.  
If a protocol deviation occurs, the investigator/delegate will inform Actelion or its representative, in a timely  manner. The investigator/delegate must document and explain 
any deviation from the approved protocol. Deviations considered to be a violation of GCP must be reported to the IRB/IEC and regulatory authorities according to Actelion or (overruling) local req uirements. 
Macitentan / ACT-[ADDRESS_327955]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 90/[ADDRESS_327956] be submitted to the IRB/IEC and regulatory authorities, 
according to their requirements.  
13.7 Essential documents and rete ntion of documents 
The investigator/delegate must maintain adequate records necessary for the reconstruction and evaluation of the study. A number of attributes are considered of universal importance to source data and the records that hold those data. These include that the data and records are accurate, legible, contemporaneous, original (or certified copy), attributable, complete, consistent, enduring, and available when needed. These records are to be classified into two different categories of documents: ISF and subject clinical source documents.  
These records must be kept by [CONTACT_180533]’s requirements (i.e., as specified in the clinical study agreement), and national 
and/or international regulati ons, whichever would be the longest period. If the 
investigator cannot guarantee this archiving requirement at the site for any or all of the documents, special arrangements, respecting the data confidentiality, must be made between the investigator and Actelion to store these documents outside the site, so that they can be retrieved in case of a regulatory inspection. No study document should be destroyed without prior written approval from Actelion. Should the investigator wish to assign the study records to another party, or move them to another location, Actelion 
must be notified in advance. If the site is using an electronic/computerized system to store subject medical records, it can be used for the purpose of the clinical study if it is validated (as per [ADDRESS_327957]) and if the monitor has been provided personal and restricted access to study subjects only, to verify consistency between electronic source data and the eCRF during monitoring visits. If the site is using an electronic/computerized system to store subject medical records but it could not be confirmed that the system is validated or if the monitor could not be provided access to the system, the site is requested to print the complete set of source data needed for verification by [CONTACT_2037]. The print- outs must be numbered, stapled 
together with a cover sheet, signed and dated by [CONTACT_093]/delegate to confirm that these certified copi[INVESTIGATOR_180461]’s data. The printouts will be considered as the official clinical study records and 
must be filed either with the subject medical records or with the subject ’s eCRF. 
Macitentan / ACT-[ADDRESS_327958]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 91/[ADDRESS_327959] for some of them 
(e.g., first subject; regular check during the study of critical data like inclusion/exclusion criteria, endpoints for some subjects) as per Actelion ’s instructions. If it were not possible 
for the monitor to observe this process, it would not be possible to rely on the site ’s 
certified copi[INVESTIGATOR_180462].  13.8 Monitoring  
Prior to study start, a site initiation visit (SIV) will be performed after the required essential study documents are approved by A ctelion. The study treatment will be shipped 
to the site upon approval of the required essential documents. The PI [INVESTIGATOR_208162]. Site Information Te chnology support should also be 
available during the initiation visit.  
The SIV must be completed before the site can start the Screening of study subjects. 
Following the SIV, a copy of the completed initiation visit report and follow -up letter 
will be prov ided to the PI [INVESTIGATOR_42876]. 
During the study, the monitor will contact [CONTACT_42947], on request, to have access to study facilities and all source documents needed to verify adherence to the protocol and the c ompleteness, consistency, and accuracy of 
the data being entered in the eCRFs and other protocol -related documents. Actelion 
monitoring standards require full verification that Informed C onsent has been provided, 
verification of adherence to the inclusion/exclusion criteria, documentation of SAEs, and the recording of the main efficacy, safety, and tolerability endpoints. Additional checks of the consistency of the source data with the eCRFs will be performed according to the study-specific monitoring plan. The frequency of the monitoring visits will be based on 
subject recruitment rate and critical data collection times.  
The PI [INVESTIGATOR_269379] [ADDRESS_327960] ’s visit (site 
visit or phone call), and that all requested subject files (e.g., ICFs, medical notes/charts, and other documentation verifying the activities conducted for the study) are available for review by [CONTACT_2037]. The required site personnel must be available during monitoring visits and allow adequate time to meet with the monitor to discuss study related issues.  
The investigator agrees to cooperate with the monitor(s) to ensure that any issues detected in the course of these monitoring visits are resolved. If the subject is hospi[INVESTIGATOR_180464] / ACT-[ADDRESS_327961]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 92/[ADDRESS_327962] be kept by [CONTACT_208289], ICH -GCP, as well as instructions from Actelion. If the site needs to transfer 
the ISF to another location and/or if site facility can no longer store the ISF, the PI [INVESTIGATOR_269380].  
If the PI [CONTACT_178486], or if the site relocates, the monitor must be notified as soon as possible.  
13.10 Audit 
Actelion’s Global Quality Management representatives may audit the investigator site 
(during the study or after its completion). The purpose of this visit will be to determine the investigator’ s adherence to ICH -GCP, the p rotocol, and applicable regulations; 
adherence to Actelion ’s requirements (e.g., SOPs) will also be verified. Prior to initiating 
this audit, the investigator will be contact[CONTACT_180536] a time for the audit.  
The investigator and staff must cooperate with the auditor(s) and allow access to all study documentation (e.g., subject records) and facilities. 
13.11 Inspections 
Health Authorities and/or IRB/IEC may also conduct an inspection of Actelion ’s clinical 
study (during the study or after its completion). 
Macitentan / ACT-[ADDRESS_327963]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 93/103 Confidential  Doc No D-17.154 
 
 Should an inspection be announced by a Health Authority and/or an IRB/IEC, the investigator must inform Actelion immediately, (usually via the monitor), that such a request has been made.  
The investigator and staff must cooperate with inspector(s) an d allow access to all study 
documentation (e.g., subject records) and study facilities. 13.[ADDRESS_327964] results from the clinical study on Actelion ’s Clinical Trial Register and 
on external/national registries, as required by [CONTACT_1769].  
Actelion’s Policy on Disclosure of Clinical Research Information can be found at: 
http://www.actelion.com/documents/corporate/policies_charters/policy_clinical -research-
information.pdf In accordance wi th the Good Publication Practices and ethical practice, the results of the 
study will be submitted for publication in a peer -reviewed journal. Study results can be 
submitted for presentation at a congress before publication in a peer -reviewed journal.  
Authorship will be determined in accordance with the International Committee of Journal 
Editors criteria, and be based on:  
• Substantial contributions to the conception or design of the study, or the acquisition, analysis, or interpretation of data; and 
• Drafting of the publication or critical review for important intellectual content; and  
• Providing final approval of the version to be published; and 
• Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integr ity of any part of the work are appropriately 
investigated and resolved.  
The list of authors of any publication of study results may include representatives of Actelion and will be determined by [CONTACT_11402]. Any study- related publication written independently by [CONTACT_215271] [ADDRESS_327965] alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent 
Macitentan / ACT-[ADDRESS_327966]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 94/103 Confidential  Doc No D-17.154 
 
 rights. Neither the institution nor the investigator should permit publication during such a review period.  
Actelion’s Policy on Scientific Publications can be found at: 
http://www.actelion.com/documents /corporate/policies_charters/policy_scientific -
publications.pdf 
Macitentan / ACT-[ADDRESS_327967]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 95/103 Confidential  Doc No D-17.154 
 
 14 REFERENCES 
[Abman 2009] Abman SH. Role of endothelin receptor antagonists in the treatment of 
pulmonary arterial hypertension. Annu Rev Med. 2009;60:13-23. 
[Antoniou 2012] Antoniou T, Prokakis C, Athanasopoulos G, et al. Inhaled nitric oxide 
plus iloprost in the setting of post -left assist device right heart dysfunction. Ann 
Thorac Surg 2012; 94(3): 792–8. 
[Argenziano 1998] Argenziano M, Choudhri AF, Moazami N, et al. Randomized, double-
blind trial of inhaled nitric oxide in LVAD recipi[INVESTIGATOR_269381]. Ann Thorac Surg 1998; 65(2): 340–5. 
[Benigni 1995] Benigni A. Defining the role of endothelins in renal pathophysiology on 
the basis of selective and unselective endothelin recep tor antagonist studies. Curr 
Opin Nephrol Hypertens 1995; 4: 349–53. 
[Chua 1992] Chua B, Krebs CT, Chua CC, et al. Endothelin stimulates protein synthesis 
in smooth muscle cells. Am J Physiol 1992; 262: E412–6. 
[Clarke 1989] Clarke J, Benjamin N, Larkin W, et al. Endothelin is a potent long lasting 
vasoconstrictor in men. Am J Physiol 1989; 257: H2033–5. 
[Davie 2002] Davie N, Haleen SJ, Upton PD, et al. ETA and ETB receptors modulate the 
proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165: 398–405. 
[de Nucci 1988] de Nucci G, Thomas R, D Orleans -Juste P, et al. Pressor effects of 
circulating endothelin are limited by [CONTACT_269426] -derived relaxing factor. Proc Natl Acad Sci U S A 1988; 
85: 9797–800. 
[Feldman 2013] Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International 
Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: Executive summary. J Heart Lung Transplant 2013; 2: 157-87. 
[Galiè 2004] Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial 
hypertension. Cardiovasc Res 2004; 61: 227–37. 
[Giaid 1993]. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin- 1 in 
the lungs of patients with pulmonary hypertension. N Engl J Med. 1993; 328: 1732–9. 
Macitentan / ACT-[ADDRESS_327968]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 96/103 Confidential  Doc No D-17.154 
 
 [Grant 2012] Grant A, Smedira N, Starling R, et al. Independent and incremental role of 
quantitative right ventricular evaluation for the prediction of right ventricular failure after left ventricular assist device implantation. J Am Coll Cardiol. 2012; 60(6): 521- 8. 
[Hirata 1993] Hirata Y, Emori T, Eguchi S. Endothelin receptor subtype B mediates 
synthesis of nitric oxide by [CONTACT_180540]. J Clin Invest 1993; 91: 1367–73. 
[Imamura 2013] Imamura T, Kinugawa K, Hatano M, et al. Bosentan improved persistent 
pulmonary hypertension in a case after implantation of a left ventricular assist device. J Artif Organs 2013; 16(1): 101–4. 
[Kirklin 2014] Kirklin JK, Naftel DC, Pagani FD, et al. Sixth INTERMACS annual 
report:A10,000- patient database. J Heart Lung Transplant 2014; 33(6): 555-64. 
[Klodell 2007] Klodell C, Morey T, Lobato E, et al. Effect of sildenafil on pulmonary 
artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg 2007; 83(1): 68- 71. 
[Kormos 2010] Kormos R, Teuteberg J, Pagani F, et al. Right ventricular failure in 
patients with the HeartMate II continuous- flow left ventricular assist device: 
incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg 2010; 139(5): 1316-24. 
[Kukucka 2011a] Kukucka M, Patapov E, Stepanenko A, et al. Acute impact of left 
ventricular unloading by [CONTACT_269427]: effect of nitric oxide inhalation. J Thorac Cardiovasc Surg 2011; 141(4): 1009-14. 
[Kukucka 2011b] Kukucka M, Stepanenko A, Potapov E, et al. Right -to-left ventricular 
end-diastolic diameter ratio and prediction of right ventricular failure with 
continuous- flow left ventricular assist devices. J Heart Lung Transplant 2011; 
30(1): 64-9. 
[LaRue 2013] LaRue SJ, Garcia -Cortes R, Ray S, et al. Treatment of secondary 
pulmonary hypertension with bosentan after left ventricular assist device implantation. J Heart Lung Transplant 2013;32([ADDRESS_327969]):S110. 
[LaRue 2015] LaRue SJ, Garcia -Cortes R, Nassif ME , Vader JM, Ray S , Ravichandran 
A, Rasalingham R , Silvestry SC , Ewald GA, Wang IW , Schilling JD . Treatment 
of Secondary Pulmonary Hypertension With Bosentan After Left Ventricular Assist Device Implantation. Cardiovasc Ther.  2015 Apr;33(2):50-5. 
[Macitentan  IB] Investigator’ s Brochure. Macitentan ACT -064992. Endothelin receptor 
antagonist, Version 12. Actelion Pharmaceuticals Ltd, November 2014. 
Macitentan / ACT-[ADDRESS_327970]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 97/103 Confidential  Doc No D-17.154 
 
 [Massaki 1998] Massaki T. The discovery of endothelins. Cardiovasc Res 1998; 39: 530–
533. [Mikus 2011] Mikus E,  Stepanenko A, Krabatsch T,  Loforte A, Dandel M,  Lehmkuhl 
HB, Hetzer R,  Potapov EV. Reversibility of Fixed Pulmonary Hypertension in 
Left Ventricular Assist Device Support Recipi[INVESTIGATOR_840]. Eur J Cardiothorac 
Surg. [ADDRESS_327971];40(4):971-7. 
[O’Callaghan 2011] O ’Callaghan DS, Savale L, Montani D, et al. Treatment of 
pulmonary arterial hypertension with targeted therapi[INVESTIGATOR_014]. Nat Rev Cardiol. 
2011;8(9):526-38. 
[Patlolla 2013] Patlolla B, Beygui R, Haddad F. Right -ventricular failure following left 
ventricle assist device implantation. Curr Opin Cardiol 2013; 28: 223-33. 
[Potapov 2011] Potapov E, Meyer D, Swa minathan M, et al. Inhaled nitric oxide after left 
ventricular assist device implantation: a prospective, randomized, doubleblind, multicenter, placebo -controlled trial. J Heart Lung Transplant 2011; 30(8): 870-8. 
[Pulido 2013] Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani A. 
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013;369:809-18. 
[Raghu 2013] Raghu G, Million- Rousseau R, Morganti A, Perchenet L, Behr J. 
Macitentan for the treatment of idi opathic pulmonary fibrosis: the randomised 
controlled MUSIC Trial. Eur Respir J. 2013 Dec;42(6):1622-32. 
[Rommel 2014] Rommel JJ, O ’Neill TJ, Lishmanov A, et al. The Role of Heart Failure 
Pharmacotherapy After Left Ventricular Assist Device Support. Heart Failure 
Clin 2014; 10: 653-660. 
[Rose 2002] Rose EA, Gelijns AC, Moskowitz AJ, et al. Long- term Use of a Left 
Ventricular Assist Device For End -stage Heart Failure. N Engl J Med 2001; 
345(20): 1435-43. 
[Slaughter 2009] Slaughter M, Rogers J, Milano C, et a l. Advanced heart failure treated 
with continuous -flow left ventricular assist device. N Engl J Med. 2009; 361(23): 
2241-51. 
[Stewart 1991] Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin- 1 in 
pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 
114: 464–9. 
[Sugawara 1996] Sugawara F, Ninomiya H, Okamoto Y, et al. Endothelin-1-
inducedmitogenic responses of Chinese hamster ovary expressing human endothelin A: the role of a wortmanninsensitive signalling pathway. Mol ec 
Pharmacol 1996; 49: 447–57. 
Macitentan / ACT-[ADDRESS_327972]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 98/103 Confidential  Doc No D-17.154 
 
 [Tedford 2008] Tedford RJ, Hemnes AR, Russell SD, et al. PDE5A inhibitor treatment of 
persistent pulmonary hypertension after mechanical circulatory support. Circ Heart Fail 2008; 1(4): 213–9. 
[Wright 2009] Wright G, Porcari JP, Foster CC et al. Placebo effects on exercise 
performance. Gundersen Lutheren Medical Journal 2009; Volume 6, Number 1. 
Macitentan / ACT-[ADDRESS_327973]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 99/[ADDRESS_327974] signs of right 
heart failure. Dyspnea and/or fatigue may even be present at rest. 
Discomfort is increased by [CONTACT_180547]. 
 
Macitentan / ACT-[ADDRESS_327975]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 100/103 Confidential  Doc No D-17.154 
 
 Appendix 2 Glossary  
 Term Definition  
Adverse Event (AE)  Any adverse change, i.e., an y unfavorable and unintended sign, 
including an abnormal laboratory finding, symptom, or disease that occurs in a subject during the course of the study, whether 
or not considered by [CONTACT_155681].  
AEs include: • Exacerbation  of a pre-existing disease.  
• Increase in frequency or intensity of a pre -existing 
epi[INVESTIGATOR_110150].  
• Disease or medical condition detected or diagnosed 
during the course of the study, even though it may have been present prior to the start of the study. 
• Continuous persistent disease or symptoms present at 
study start that worsen following the start of the study (i.e., signing of informed consent). 
• Abnormal assessments, e.g., change on physical 
examination, ECG findings, if they represent a clinically 
significant finding that was not present at study start or 
worsened during the course of the study. 
• Laboratory test abnormalities if they represent a 
clinically significant finding, symptomatic or not, which was not present at study start or w
orsened during the 
course of the study or led to dose reduction, interruption or permanent discontinuation of study treatment. 
A treatment -emergent AE is any AE temporally associated with 
the use of study treatment (from study treatment initiation until 30 
days after study treatment discontinuation) whether or not 
considered by [CONTACT_86190]. 
Baseline The last value obtained prior to first dose of study treatment . 
Baseline Right Heart 
Catheterization (RHC) The last hemodyn amic measurements after LVAD implantation 
and prior to the first dose of study treatment.  
Macitentan / ACT-[ADDRESS_327976]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 101/[ADDRESS_327977] one of the following criteria:  
• Previous bilateral salpi[INVESTIGATOR_8820] y, bilateral salpi[INVESTIGATOR_8936] -
oophorectomy or hysterectomy. 
• Premature ovarian failure confirmed by a specialist.  
• Pre-pubescence, XY genotype, Turner syndrome, 
uterine agenesis.  
• Post-menopausal, defined as 12 consecutive months 
with no menses without an alternative  medical cause 
(International Council for Harmonisation [ICH] M3 
definition).  
Hemoglobin recovery  Return of hemoglobin above the lower limit of the normal range 
or return to a value close to that at Baseline.  
Hospi[INVESTIGATOR_247501] (HF)  A hospi[INVESTIGATOR_269372].  
Intensity of adverse 
events Mild 
• The event may be noticeable to the subject. It does not 
influence daily activities, and usually does not require 
intervention. 
Moderate  
• The event may make the subject unc omfortable. 
Performance of daily activities may be influenced, and intervention may be needed. 
Severe 
• The event may cause noticeable discomfort, and usually interferes with daily activities. The subject may not be able to continue in the study, and treatme
nt or 
intervention is usually needed.  
Medical history  • Chronic medical conditions and new acute medical 
conditions within the past 6 months (e.g., anemia, 
hepatitis C infection, HIV infection, obstructive or 
restrictive lung disease, hypertension, renal di sease) 
• Any previous life -threatening conditions, including date 
(e.g., myocardial infarction).  
Moderate to severe 
restrictive lung disease (an exclusion 
criterion) Total lung capacity < 60% of predicted value.  
Macitentan / ACT-[ADDRESS_327978]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 102/[ADDRESS_327979]-menopausal  Twelve consecutive months wi th no menses without an 
alternative medical cause (ICH M3 definition).  
Previous therapy  Any treatment for which the end date is prior to the signing of 
informed consent 
Pulmonary 
Hypertension (PH) • Mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg 
and 
• Pulmonary artery wedge pressure (PAWP) ≤ 18 mmHg 
and 
• PVR > 3 Wood units.  
Serious Adverse Event 
(SAE), as per ICH guidelines Any AE fulfilling at least one of the following criteria  
• Fatal. 
• Life-threatening: refers to an event in which the subject 
was at risk of death at the time of the event. It does not 
refer to an event that hypothetically might have caused death had it been more severe.  
• Requiring inpatient hospi[INVESTIGATOR_059], or prolongation of 
existing hospi[INVESTIGATOR_059]. 
• Resulting in persistent or significant d isability or 
incapacity. 
• Congenital anomaly or birth defect. 
• Medically significant: refers to important medical events 
that may not immediately result in death, be 
life-threatening, or require hospi[INVESTIGATOR_269382], based up on appropriate 
medical judgment, they may jeopardize the subject, and may require medical or surgical intervention to prevent 
one of the outcomes listed in the definitions above.  
Severe obstructive 
lung disease (an exclusion criterion) Forced expi[INVESTIGATOR_696] v olume in 1 second / forced vital capacity 
(FEV1/FVC) < 0.7 associated with FEV 1 < 50% of predicted 
value after bronchodilator administration.  
Macitentan / ACT-[ADDRESS_327980]-LVAD implantation  
Protocol AC -055-205, SOPRANO  
Version 3 
10 March 2017 , page 103/103 Confidential  Doc No D-17.154 
 
 Stabilization of the 
patient for 48 h prior to the Baseline RHC  • No LVAD pump speed/flow rate changes  
and 
• Stable dose of oral diuretics  
and 
• No intravenous (i.v.) inotropes or vasopressors and 
• Patient able to ambulate  
Study -concomitant 
therapy Any treatment for which the start date is on or after the signing 
of Informed Consent up to 30 days after study treatment 
discontinuation. 
Study treatment  Administration of double -blind study drug (macitentan or 
placebo). 
Study treatment -
concomitant Any treatment for which the start date is on or after the first 
administration of study treatment up to Week 12 or earlier in case of premature discontinuation of study treatment. 
 